

TITOMIC

ANNUAL REPORT

FOR THE SIX MONTHS ENDED 31 DECEMBER 2025

Titomic Limited

ABN 77 602 793 644

TABLE OF CONTENTS



ADDITIVE MANUFACTURING APPLICATIONS

STRUCTURES

Cold spray creates large structures with minimal size constraints from titanium, steel, and more, comparable to the properties of cast or forged parts with shorter lead time and less waste.

BALLISTICS SHIELDING

Create complex, freeform ballistics protection from multiple metals or titanium to produce larger, lighter, more versatile armour.

TOOLING

Produce stronger, lighter, thinner and corrosion-resistant near-net shape faceplates – with reduced welding, assembly and lead times.

COATING & REPAIR APPLICATIONS

FUNCTIONAL COATINGS

Heat-resistant layers, electrical conductivity, anti-fouling properties, and antibacterial surfaces, all achievable with significant thickness, no thermal distortion, unlimited size capacity, and on-site application.

CORROSION

Apply corrosion-resistant materials such as titanium, aluminium, zinc, and nickel to new or existing parts, enhancing their lifespan in corrosive environments across marine, chemical, and oil and gas applications.

WEAR RESISTANCE

Protect moulds, handling equipment, and more from wear, and replace hard chrome coatings

ENGINE REMANUFACTURING

Refurbish engines without heat to restore and protect components, enhancing durability and performance with a cost- effective, easy to use solution.

EMBEDDED SENSORS

Build and incorporate electronic sensors directly into parts, providing hard-wearing and anti-corrosion analytical sensors for offshore oil and gas, subterranean piping and more.

REPAIRS

Rapidly repair metal parts, restoring them to working order in applications across aerospace, mining, defense, boilermaking and more. Spray metal in seconds, so your coating & repair applications can restore parts in minutes.

MINIMIZE DOWNTIME, MAXIMIZE PRODUCTION

Cold spray accelerates metal powders to supersonic speeds, carried by air or nitrogen. As the powders exit the nozzle, they collide and mechanically bond to the surface and each other. As millions of powder particles collide every minute, they quickly build up strong, high-adhesion layers of metal to create coatings or free-form, 3D parts. Unlike traditional manufacturing methods like casting or forging, the particles don't need to melt to be bonded together. This results in several significant capabilities, including:

- Parts are made to a near-net shape, reducing the amount of material that needs to be removed from the part by up to 90%, significantly reducing material costs.
- As the metals aren't melted, cumulative thermal stress is mitigated and an inert environment is not needed, enabling Titomic to manufacture parts with minimal size constraints.
- Metals with different melting points are still able to be combined into a single, seamless part, such as aluminium and titanium, steel and copper, and much more. This allows manufacturers to leverage the strengths of multiple metals in a single part or coating.

FASTER OUTPUT

SCALABLE SYSTEMS

COMBINE METALS

NO SIZE RESTRICTIONS

COST COMPETITIVE

LESS WASTE

TITOMIC OVERVIEW

The world's leading provider OF COLD SPRAY SOLUTIONS

Titomic is the world's only publicly listed company with cold spray at the core of its operations. With this technology, Titomic is providing new capabilities for the manufacture, coating, and repair of metal parts.

SYSTEMS

Faster, stronger metal coatings and repairs

For the repair and restoration of numerous metal parts like engine components and moulds, sealing, corrosion protection, electrical conductivity and special applications.

Greater process control and efficiency

Titomic's turnkey Integrated Spray Booth systems bring together low-to-medium pressure cold spray, handling, and dust extraction.



Create large, strong multi-metal parts

Titomic's **TKF™1000** is a modular additive manufacturing system. Limitless possibilities including prototyping to R&D, small-run production and on-demand manufacturing.

TKF 3250

Leading cold spray manufacturing capability

Titomic's capability to meet industry demands with high-performance cold spray systems. Designed and optimised for aerospace and defense manufacturing.

Chairman & CEO Letter

Dear Shareholders,

The United States and its allies are rebuilding sovereign manufacturing capacity in response to heightened national security demands, propulsion modernization, naval sustainment expansion, semiconductor capacity constraints, and critical infrastructure resilience requirements. The U.S. Department of War has made clear that industrial availability and speed of production are now strategic imperatives.

Titomic operates directly within this transformation.

We are building production-scale cold spray manufacturing and sustainment capability inside the U.S. and allied defense industrial base to improve readiness, reduce lead times, and strengthen sovereign supply chains.

Titomic provides manufacturing and sustainment capacity at speed.

THE INDUSTRIAL CONSTRAINT

Modern propulsion systems, naval platforms, semiconductor manufacturing equipment, and critical infrastructure increasingly depend on long-lead casting and forging supply chains that cannot meet current operational timelines.

Availability is now as important as performance.

Titomic Kinetic Fusion™ (TKF™) enables the production and sustainment of mission-critical metal components without melting, reducing dependency on constrained supply chains and enabling repair-over-replace economics.

FROM QUALIFICATION TO PRODUCTION

Modern defense and semiconductor supply chains continue to experience long lead times associated with casting and forging dependencies. Titomic Kinetic Fusion™ (TKF™) enables production and sustainment of mission-critical metal components without melting, reducing supply chain exposure and enabling repair-over-replace economics.

During the period, Titomic advanced multiple programs along a defined pathway:

Qualification → Low Rate Initial Production (LRIP) → Production → Sustainment

Key milestones include:

- Successful hot fire validation of a solid rocket motor thrust chamber for a major U.S. defense prime
- Execution of a USD $1.7 million Early Manufacturing Development contract in Huntsville
- Transition of semiconductor manufacturing validation programs into Low Rate Initial Production
- Ukrainian Army confirmation of successful TKF™ 523 near peer fighting repair capabilities.
- Expansion of corrosion repair and sustainment programs aligned with naval and energy infrastructure operators
- Execution of a NASA Space Act agreement supporting aerospace manufacturing integration

These programs demonstrate repeatability and progression toward production-scale deployment.

Why Customers Adopt Titomic

Customers adopt Titomic because operational readiness increasingly depends on:

Speed – delivery in weeks rather than months
Availability – repair near the point of need
Quality – high structural integrity with no phase change/high temperature distortion
Resilience – domestic manufacturing capability

The result is repair-over-replace economics while improving uptime of mission-critical systems.

This value proposition aligns directly with current defense industrial policy priorities.

SCALING INSIDE THE DEFENSE INDUSTRIAL BASE

In 2025, Titomic established Huntsville, Alabama as its Global Headquarters, positioning our primary expansion inside the U.S. defense industrial base. We also established a brand-new highly automated factory in Heerenveen, Holland ideally positioned to support the key European markets.

We strengthened our balance sheet and aligned our capital strategy with U.S. industrial expansion priorities, including submission of a preliminary business plan under the EXIM Bank "Make More in America" initiative to support domestic manufacturing scale-up.

These initiatives are designed to accelerate production capacity — not research activity — and align directly with our industrial platform strategy.

OUR PEOPLE

Titomic's strategy requires deep operational, manufacturing and defense domain expertise.

At year-end 2025, Titomic employed 83 full-time personnel globally, with expanded engineering, manufacturing and program execution teams in Huntsville, Heerenveen and Melbourne.

During the period, we strengthened leadership across manufacturing and regional operations, appointing a Senior Vice President of Manufacturing, a President APAC and a President Europe to support production scaling and regional execution.

Our Board was strengthened with additional defense leadership experience, and we formalized a U.S. Strategic Advisory Group comprised of senior aerospace and defense executives to support strategic engagement, industrial partnerships and government alignment.

Our team is focused on one objective: advancing programs from qualification to production and sustainment at speed.

OUR ROLE

Titomic is building a production-scale cold spray manufacturing platform positioned inside the U.S. and allied defense industrial base.

We are building an industrial platform designed to provide manufacturing and sustainment capacity where national security and critical infrastructure require availability, speed and resilience.

Our focus is execution: expanding deployment across programs already integrating our capability into operational workflows.

The reindustrialization of allied manufacturing is underway. Titomic intends to be part of that foundation.

On behalf of the Board and management team, we thank our employees, customers, partners and shareholders for their continued support.

Sincerely,

DAG W.R. STRØMME
Executive Chairman

JIM SIMPSON
CEO & Managing Director



SUCCESSFUL HOT FIRE TEST ON A SOLID ROCKET MOTOR THRUST CHAMBER ADDITIVELY MANUFACTURED BY TITOMIC'S TKF™ COLD SPRAY

Titomic announced the successful hot fire test of a solid rocket motor thrust chamber manufactured using its TKF™ technology for a major U.S. aerospace and defense prime. The milestone validates the performance, durability, and rapid manufacturability of cold spray additive manufacturing for mission-critical propulsion applications. This validation demonstrates the transition of TKF™ propulsion components from qualification toward production integration within defense prime supply chains.

TITOMIC SECURED EARLY MANUFACTURING DEVELOPMENT CONTRACT WITH LEADING DEFENSE PRIME

Titomic secured a USD 1.7 million (AUD 2,550,000) Early Manufacturing Development contract with a leading defense prime to develop and validate advanced manufacturing pathways for next-generation defense articles. The program, to be executed at Titomic's Huntsville facility, aims to accelerate production, strengthen supply-chain resilience, and support faster delivery of critical components to the warfighter.

UKRAINIAN ARMY CONFIRMATION OF SUCCESSFUL TKF™ 523 NEAR PEER FIGHTING REPAIR CAPABILITIES.

The Ukrainian Army confirmed the value added utilization and important contribution of Titomic's in field repair capabilities, asking for increased powder usage and additional systems. Titomic's board of directors approved the donation of two additional TKF™ 523 systems in the fall of 2025 and it is expected that further machine orders for Ukraine will materialize in 2026.



TITOMIC SECURED PURCHASE ORDER FOR LOW RATE INITIAL PRODUCTION WITHIN THE SEMICONDUCTOR SECTOR

Titomic secured its first Low Rate Initial Production (LRIP) order for specialized semiconductor components, marking a key commercial milestone following successful validation of its Titomic Kinetic Fusion™ process. The order positions the Company to transition into full-scale production in 2026 and expand its presence in high-performance manufacturing markets. The LRIP milestone establishes a defined pathway toward full production scaling in 2026.

TITOMIC'S TKF™ 623 TO BE USED FOR OIL & GAS

Titomic has secured a six-month lease for its TKF™ 623 cold spray system from a major energy operator, following successful trials of the smaller TKF™ 523. The agreement demonstrates strong industry confidence, showcasing the TKF™ 623's ability to deliver efficient corrosion protection, rapid repairs, reduced downtime, and long-term operational value.

OPENING OF NEW, ROBOTICIZED 25 000 SQUARE FEET MANUFACTURING FACILITY IN HEERENVEEN, HOLLAND.

Following the opening of Titomic's U.S. facility in Huntsville, the company opened up a hypermoderne manufacturing facility in Heerenveen, Holland in September 2025. Titomic is now supporting domestic manufacturing and repair capabilities with state-of-the art facilities in the U.S., Europe as well as Australia.

Driving Innovation, Securing the Future

GLOBAL EXPANSION MAP



ROADMAP TO 2030

Demonstration & validation with primes
2025 - 2026

Initial production roll-outs and rapid expansion
Targeting multi-program production contracts across propulsion systems, naval sustainment, and semiconductor manufacturing.
2026 – 2027

Multi-sector penetration
2028 – 2029
Defense, Oil & Gas, MRO

Defense & Aerospace
Oil & Gas/Maritime
MRO/Aviation
Transportation
Systems/Leasing

Scale achieved with diversified revenues
2030

TECHNOLOGY ADVANTAGE



COMMERCIAL PROGRESS

Aerospace/Defense	Marine/Energy	Transport/Industry	Academia
Northrop production, Tier 1 prime engagement, NAVSEA sales	Active Oil & Gas corrosion repair	50+ rail repairs; Hydraulex & Metric Auto sales	UNT, OMIC R&D, Limoges, Fraunhofer

DIRECTORS' REPORT

TITOMIC

THE DIRECTORS

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Consolidated entity') consisting of Titomic Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the six months ended 31 December 2025

DIRECTORS AND COMPANY SECRETARY

The following persons were directors and company secretary of Titomic Limited during the whole of the period and up to the date of this report, unless otherwise stated:

MR. DAG W.R. STRØMME
EXECUTIVE CHAIR

MR. HUMPHREY NOLAN
INDEPENDENT NON-EXECUTIVE DIRECTOR

DR. ANDREAS SCHWER
INDEPENDENT NON-EXECUTIVE DIRECTOR

MS. MIRA RICARDEL
INDEPENDENT NON-EXECUTIVE DIRECTOR

MR. JOHN FREWEN, AO, DSC
INDEPENDENT NON-EXECUTIVE DIRECTOR
APPOINTED 1 JULY 2025

MR. RICHARD WILLSON
INDEPENDENT NON-EXECUTIVE DIRECTOR
RETIRED 1 JULY 2025

MR. JIM SIMPSON
MANAGING DIRECTOR

MR. GEOFF HOLLIS
CFO AND COMPANY SECRETARY

PRINCIPAL ACTIVITIES

Titomic Limited is an ASX listed company headquartered in Huntsville, Alabama, United States with operations in Melbourne, Australia and Heerenveen, The Netherlands. Titomic, with its patented cold spray technology, Titomic Kinetic Fusion™, delivers efficient production-scale capabilities for the manufacture and sustainment of large, high-performance components and critical assets. By delivering new manufacturing possibilities and enhanced performance, Titomic offers novel, rapid, and efficient manufacturing and sustainment outcomes across aerospace, defense, energy, and other advanced industrial sectors. The Company's strategic focus prioritizes propulsion components, naval sustainment, semiconductor manufacturing support, and energy infrastructure resilience within the U.S. and allied defense industrial base.

INFORMATION ON DIRECTORS AND KEY MANAGEMENT PERSONNEL

MR. DAG W.R. STRØMME
EXECUTIVE CHAIR

Mr. Strømme is an investor and entrepreneur with over 30 years of experience from successful private ownership and leading European, as well as global, financial institutions. He has been running his own family investment office, PAACS Invest, since 2015.

Mr. Strømme was previously a senior industry advisor to Triton, an investment firm with €17B under management. He joined Morgan Stanley in New York in 1990, focusing on mergers and acquisitions and was a Managing Director of Morgan Stanley London from 2001 to 2007 and Co- Head of Nordic Investment Banking from 2000 to 2007. Mr. Strømme has been a director of various public and non-public companies. He is currently controlling shareholder and Chairman of Racom AS, a technology company focused on security for public and private sector, and a director of software company Arundo.

MR. HUMPHREY NOLAN
INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr. Nolan is a seasoned Board Director and CEO with 30 years' experience driving strategic and operational change across industrial, logistics and distribution industries.

Mr. Nolan has held senior leadership positions within global logistics companies, including at the P&O Group. Mr. Nolan is currently Chairman of both the Nolan Group and Tapex Group, both leading distributors of technical and industrial textiles operating across Australia and New Zealand.

DR. ANDREAS SCHWER
INDEPENDENT NON-EXECUTIVE DIRECTOR

Through his extensive 25-year executive career across the global defense and aerospace industries, Dr. Schwer has gained a wealth of experience, insight and a deep understanding, which he brings to the board of Titomic Limited. Dr. Schwer's executive track record is world-class, holding executive positions across a multitude of high-value industries, including Saudi Arabian Military Industries' inaugural CEO, where he grew the business from a greenfield operation to become a prominent entity in the international defense market.

Prior to this achievement, Dr. Schwer held the role of Chairman, President, and CEO of Rheinmetall International and CEO of Combat Systems Division, both branches of international defense prime, Rheinmetall AG. Prior to joining Rheinmetall, Dr. Schwer held various executive management positions, including 12 years at Airbus Group's Defense & Space and Helicopters divisions and an executive role at the equipment manufacturing group, The Manitowoc Company. Dr. Schwer is the Managing Director of Electro Optic Systems Ltd.

THE HONORABLE MIRA RICARDEL
INDEPENDENT NON-EXECUTIVE DIRECTOR

Ms. Ricardel is a recognized leader and national security expert with extensive experience in aerospace and defense, geopolitical risk, and regulatory matters with a focus on international investment, export controls, and supply chain security. She serves on the Proxy Board of Astroscale U.S. Inc., a subsidiary of Japan-based Astroscale. Ms. Ricardel is on the board of the non-profit organization, the Center for American Medicine Resiliency. She is a Senior Advisor at The Chertoff Group.

Ms. Ricardel has held Presidential appointments at the U.S. Department of Commerce and The White House. At The White House she served as the Deputy National Security Advisor and Assistant to the President. Prior to that she was confirmed by the U.S. Senate as the Under Secretary of Commerce for Export Administration, leading the Bureau of Industry and Security. For nearly a decade Ms. Ricardel was a vice president of business development in Network & Space Systems at The Boeing Company. Immediately prior to and following 9/11, Ms. Ricardel served as Deputy Assistant Secretary of Defense for Eurasia and then Acting Assistant Secretary of Defense for International Security Policy. Earlier in her career, Ms. Ricardel held positions at the State Department and on Capitol Hill.

MR. JOHN FREWEN AO, DSC
INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr. Frewen served over 40 years in the Australian Defence Force, commanding at every level from Infantry Platoon to all Australian Forces in the Middle East. He later held senior roles including Principal Deputy Director General of the Australian Signals Directorate, Chief of Joint Capabilities, and Coordinator General of the National COVID-19 Vaccine Task Force. Honored with the AO and DSC, Mr. Frewen now advises leading defense and technology organisations.

MR. JIM SIMPSON
MANAGING DIRECTOR

Mr. Simpson brings more than 40 years of experience in the satellite, aerospace, and defense sectors, holding executive leadership positions across prestigious organisations. His career highlights include serving as CEO of Saturn Satellite Networks and ABS Corporation, as well as senior leadership roles at Virgin Orbit, Aerojet Rocketdyne, and Boeing. With a deep understanding of U.S. national security, international, commercial, and civil space operations, Mr. Simpson is recognised as a visionary leader in the industry.

Mr. Simpson holds a B.S. and M.S. in Engineering from UCLA and an M.B.A. from USC. He is a distinguished member of the American Institute of Aeronautics and Astronautics (AIAA) and the Beta Gamma Sigma Business Honor Society.

As Managing Director and CEO of Titomic, Mr. Simpson is spearheading efforts to accelerate the commercial adoption of Titomic's cutting-edge cold spray technology, particularly within the defense and aerospace sectors. His leadership is driving strategic partnerships and positioning Titomic as a transformative force in advanced manufacturing, delivering innovative solutions to meet the evolving needs of mission-critical industries.

MR. GEOFF HOLLIS
CFO AND COMPANY SECRETARY

Mr. Hollis brings a wealth of financial expertise and strategic leadership to Titomic. With a strong background in guiding ASX-listed companies through significant growth and transformation, he has a proven track record in enhancing operational efficiency and financial performance. Previously, Mr. Hollis has served as CFO and Company Secretary of Lifestyle Communities Limited, Victory Offices Limited and Imagion Biosystems Limited after ten years in a prominent chartered accounting firm. His comprehensive skill set in capital markets, debt financing, and investor relations positions him as a key contributor to Titomic's ongoing success and innovation.

DR. PATRICIA DARE
PRESIDENT, USA

Dr. Dare is a highly accomplished leader with over 30 years of expertise in the aerospace and defense sectors. As Titomic USA's Aerospace & Defense Lead, Dr. Dare is at the forefront of commercialising Titomic's innovative cold spray technology, enabling advanced manufacturing solutions for mission-critical applications. Her work is driving transformation in the industry, offering cutting-edge repair, restoration, and manufacturing capabilities to support the needs of defense and aerospace customers across the United States.

Dr. Dare's distinguished career includes senior leadership roles at Raytheon Technologies, Boeing, Lockheed Martin, and Honeywell International, where she excelled in program management, business development, and strategic growth. With a Doctor of Philosophy in Chemistry, Dr. Dare combines technical insight with a deep understanding of the defense and aerospace landscapes, making her a trusted advisor and industry expert.

MR. KLAAS ROZEMA
PRESIDENT, EMEA

Mr. Rozema is a leading innovator and expert in cold spray technology, with a distinguished career marked by significant contributions to the field. As the founder of Dycomet, Mr. Rozema spearheaded advancements in cold spray solutions, bringing cutting-edge technology to over 100 customers across various industries. Following Titomic's acquisition of Dycomet, Mr. Rozema transitioned to serve as President of the EMEA region, where he continues to drive growth and innovation. In his role at Titomic, Mr. Rozema leads the team and activities in Europe, the Middle East, and Africa, leveraging his expertise to expand the reach of Titomic's revolutionary cold spray systems. His leadership and vision ensure that Titomic remains at the forefront of additive manufacturing and advanced repair solutions for mission-critical applications.

MS. AUDE VIGNELLES
PRESIDENT, APAC

Ms. Vignelles is the APAC President of Titomic, revolutionizing high-performance production with advanced metal solutions that enable faster turnaround, superior strength, and enhanced sustainability. Until April 2024, Ms. Vignelles served as the inaugural Chief Technology Officer of the Australian Space Agency, where she was instrumental in developing the civil space strategy's technical roadmaps, scoping and managing the Agency's space programs and delivering on domestic and international activities. Prior to this role, Ms. Vignelles was the Executive Manager of Satellite & Fixed Wireless Operations at NBN.

Ms. Vignelles is a space and aeronautics engineer, graduating from ENSICA (now ISAE-SUPAERO) in Toulouse, and began her career at the European Space Agency (ESA) in the Netherlands where she became a key expert in the test campaigns of scientific programs, including the Rosetta mission. She was appointed Test Manager for the X-ray Multi-Mirror Mission (XMM), ESA's largest scientific space program at the time.

Having lived in Australia for the past 23 years, Ms. Vignelles has significantly contributed to the Australian space community and the establishment of the Australian Space Agency.



INFORMATION ON STRATEGIC ADVISORY GROUP

JIM CHILTON

Mr. Chilton is a senior aerospace and defense executive with nearly 40 years of leadership at Boeing, most recently serving as Senior Vice President and Senior Advisor to Boeing Defense, Space & Security. He previously led Boeing Defense's Space & Launch division, overseeing major programs including the International Space Station, Space Launch System, CST-100 Starliner, satellite systems, and Boeing's role in United Launch Alliance. A member of the International Academy of Astronautics and its Board of Trustees, Mr. Chilton holds engineering degrees from Washington State University and Florida Institute of Technology and completed the Advanced Management Program at Harvard Business School.

LTC (RET.) RICH CHOPPA

Rich Choppa brings more than 40 years of military and aerospace leadership experience to Titomic. Currently President of DellaCioppa Consulting, he retired from Boeing in 2020, where he most recently served as Program Director for ICBM Sustainment, and previously as leader of Global Sales and Marketing for the Missile & Weapons Systems division. Before joining Boeing, he served 21 years in the United States Army, retiring as a Lieutenant Colonel following multiple combat deployments, embassy and foreign military postings, and senior Pentagon policy assignments, bringing extensive operational, strategic, and executive expertise to support Titomic's growth across defense and aerospace markets.

ANDY HAEUPTLE

Mr. Haeuptle brings more than 44 years of senior military and civilian leadership experience within the U.S. Department of Defense to Titomic's U.S. Strategic Advisory Group. Most recently Director of the Navy Staff, he advised the Chief of Naval Operations on manning, training, and equipping the Navy, supporting oversight of 650,000 personnel and a $245 billion budget. He previously served as Senior Director of the White House Situation Room and as Chief of Staff to the Under Secretary of the Navy. A retired U.S. Marine Corps Colonel, Andy provides Titomic with deep expertise in defense operations, strategic leadership, and enterprise-level management.

MICHAEL KIRKPATRICK

Mr. Kirkpatrick is Chairman of DESE Research, Inc., headquartered in Huntsville, Alabama, where he leads the company in delivering advanced engineering, scientific, and technical solutions to U.S. Government and industry customers across Energy, Defense, Space, and Environmental programs. With extensive experience supporting mission-critical national security and aerospace initiatives, he has guided DESE in providing high-performance technical services and innovative systems integration solutions aligned with evolving federal and commercial requirements. His leadership emphasizes technical excellence, operational agility, advanced technologies, and strong government-industry partnerships that strengthen U.S. technological and industrial capabilities.

LT. GEN (RET.) HENRY "TREY" OBERING

Mr. Obering is a retired U.S. Air Force senior acquisition leader and former Director of the U.S. Missile Defense Agency, where he led the development, testing, and fielding of the nation's ballistic missile defense systems. Following his military service, he served as a senior executive at Booz Allen Hamilton, advising on defense strategy, advanced technologies, and national security programs. With deep expertise in missile defense, complex systems acquisition, and large-scale defense program execution, Mr. Obering brings strategic leadership and technical insight to Titomic, supporting the company's expansion across aerospace, defense, and advanced manufacturing markets.

JOHN SCHUMACHER

Mr. Schumacher is a distinguished aerospace executive and government leader who previously served as Chief of Staff at NASA, where he played a pivotal role in advancing national space policy, agency strategy, and cross-sector collaboration. He also held senior leadership positions at Aerojet Rocketdyne, serving as Vice President and contributing to the growth and innovation of advanced propulsion and defense technologies. With decades of experience spanning federal leadership and the commercial aerospace industry, Mr. Schumacher brings deep expertise in strategic development, government relations, and high-performance engineering systems to Titomic, supporting the company's mission to deliver cutting-edge cold spray additive manufacturing solutions to the global aerospace and defense markets.

JOHN STOPHER (PHD)

Dr. Stopher is a distinguished national security and space policy leader who previously served as Principal Assistant to the Secretary of the Air Force for Space, where he helped guide U.S. space strategy, policy, and program oversight. He also served as Budget Director for the U.S. House Special Select Committee on Intelligence, overseeing funding and fiscal strategy for critical intelligence programs. With deep expertise in defense budgeting, space systems, and national security policy, Dr. Stopher brings strategic insight and government-level experience to Titomic, supporting the company's growth across aerospace, space, and defense markets.

Directors' Report

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Titomic Limited (referred to hereafter as the 'Company' or 'parent entity' or 'Titomic') and the entities it controlled at the end of, or during the six months ended 31 December 2025.

Directors

The following persons were directors and company secretary of Titomic Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Mr Dag W.R. Stromme	Executive Chair
Mr Humphrey Nolan	Independent Non-Executive Director
Mr Andreas Schwer	Independent Non-Executive Director
Ms Mira Ricardel	Independent Non-Executive Director
Mr John Frewen, AO, DSC	Independent Non-Executive Director (appointed 1 July 2025)
Mr Richard Willson	Independent Non-Executive Director (resigned 1 July 2025)
Mr Jim Simpson	Managing Director
Mr Geoff Hollis	CFO and Company Secretary

Principal activities

Titomic Limited is an ASX listed company headquartered in Huntsville, Alabama, United States with operations in Melbourne, Australia and Heerenveen, The Netherlands. Titomic, with its patented cold spray technology, Titomic Kinetic Fusion™, delivers efficient production-scale capabilities for the manufacture and sustainment of large, high-performance components and critical assets. By delivering new manufacturing possibilities and enhanced performance, Titomic offers novel, rapid, and efficient manufacturing and sustainment outcomes across aerospace, defense, energy, and other advanced industrial sectors. The consolidated entity's strategic focus prioritizes propulsion components, naval sustainment, semiconductor manufacturing support, and energy infrastructure resilience within the U.S. and allied defense industrial base.

Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Change of financial year end

The consolidated entity elected to change its financial year end from 30 June to 31 December to align its reporting dates with its United States and Netherlands based subsidiaries. This financial report is for the six months ended 31 December 2025, with the comparative period being the 12 months ended 30 June 2025. As a result, the amounts presented in the consolidated financial statements are not directly comparable.

Review of operations

Operating loss for the six months ended 31 December 2025 after providing for income tax of $17,851,299 (12 months ended 30 June 2025: $19,886,876 loss) was materially in line with expectations. During the six months the consolidated entity incurred increased operating expenditure reflecting deliberate investment in U.S.-based production capacity, certification progression, and operational scaling aligned with defense industrial demand. The consolidated entity continued its transition toward recurring production and sustainment revenue streams. Refer below and prior in this report for further discussion.

Revenue and other income

Total revenue for the six months ended 31 December 2025 was $5,270,650 (12 months ended 30 June 2025: $9,427,102).

Revenue from contracts with customers for the six months ended 31 December 2025 was $4,008,246 (12 months ended 30 June 2025: $8,114,049). Underpinning revenues in the six months ended 31 December 2025 were revenues from $1,692,025 sale of high-pressure and medium-pressure cold spray systems to Triton System Inc., as well as the recognition of the remaining revenue of $650,275 from University of North Texas and OMIC R&D systems sales. Other sales revenue comprised key prototyping and manufacturing validation contracts as well as $440,205 from low-pressure machines sales.

Other revenue for the six months ended 31 December 2025 was $1,262,404 (12 months ended 30 June 2025: $1,313,053), this period primarily comprised of interest received, grant income received and sub-lease rental income.

Operating expenses

Total expenses for the six months ended 31 December 2025 were $23,121,949 (12 months ended 30 June 2025: $29,517,601). Included in expenses are non-cash related costs (share based payments, depreciation, amortisation and notional interest expenses) of $4,302,143 (12 months ended 30 June 2025: $6,496,163).

Production and related expenses

Production and related expenses for the six months ended 31 December 2025 were $6,977,975 (12 months ended 30 June 2025: $8,297,785). Included are all costs of production such as material, salaries and wages factory related costs as well as research and development expenses. The increase in annualised production and related expenses is mainly due to the consolidated entity's significant expansion in the United States together with system sales to U.S. based customers with expenses for the six months ended 31 December 2025 of $3,716,452 (12 months ended 30 June 2025: $3,487,602).

Corporate and administrative expenses

Corporate and administrative expenses for the six months ended 31 December 2025 were $9,418,307 (12 months ended 30 June 2025: $11,161,085). The increase in annualised expenses is mainly due to the consolidated entity's significant expansion in the United States with expenses for the six months end 31 December 2025 of $5,133,534 (12 months ended 30 June 2025: $4,258,893). Corporate and administrative expenses in Australia and Europe have remained relatively consistent.

Sales, marketing and promotion expenses

Sales, marketing and promotion expenses for the six months ended 31 December 2025 were $1,926,415 (12 months to 30 June 2025: $3,282,888). Sales, marketing and promotion expenses include direct marketing costs, salaries and wages related to sales and marketing employees and sales related travel expenses (i.e. for trade shows). The increase in annualised expenses is shared across geographical regions and reflects increased sales and marketing efforts by the consolidated entity which is expected to lead to revenue growth in 2026 and beyond.

Liquidity

The consolidated entity had cash at 31 December 2025 of $35,765,201 (30 June 2025: $8,926,447). Following the completion of $50,000,000 capital raise in July 2025, the consolidated entity is positioned with sufficient funding to execute its strategic growth initiatives in the United States, Europe and Australia. The strengthened balance sheet de-risks execution and provides flexibility to pursue large-scale defense and aerospace opportunities.

Outlook

The consolidated entity expects material revenue growth in the 2026 calendar year, driven by production manufacturing contracts with defense primes, expanded sustainment work within energy and maritime sectors, and the sale and lease of machines. With a strengthened balance sheet and improving gross margins and utilisation, the consolidated entity anticipates operating leverage as global and in particular, U.S., production matures. While the consolidated entity remains in an investment phase, management is targeting significant progress towards annualised operating cash flow breakeven in the 2027 calendar year.

Titomic Limited
Directors' Report
For the six months ended 31 December 2025

Significant changes in state of affairs

During the six months ended 31 December 2025 the consolidated entity continued its U.S. expansion in its relatively new global headquarters in Huntsville, Alabama (which settled in June 2025). In addition to this, the consolidated entity opened its new European facility in Heerenveen, The Netherlands in September 2025. Both facilities, along with the consolidated entity's original facility in Australia, are now fully operational with Huntsville to get an additional high-pressure cold spray system (ready in April 2026) to meet expected additional U.S. based production manufacturing demand.

Matters subsequent to the end of the financial year

There is no matter or circumstance that has arisen since 31 December 2025 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Likely developments and expected results of operations

With the facilities in Huntsville, Alabama and Heerenveen, The Netherlands now largely complete, quarterly cash burn will be significantly reduced, and the Company is well positioned to grow its top line and cash flow. The consolidated entity has a strong focus on executing the pipeline of current opportunities and expanding marketing and outreach efforts to ensure the consolidated entity's capabilities are well known by Tier 1 defense and aerospace primes, maritime and energy organisations who have manufacturing and sustainment needs including coating and repair opportunities. Global defense and sovereign manufacturing investment continues to expand. The U.S. defense budget for 2026 is ~US$1 trillion with President Trump having announced another US$500 billion increase for 2027, while the European Union has announced more than €800 billion in defense funding through 2030. These structural demand drivers, coupled with the global push for resilient and sovereign supply chains, provide a supportive environment for the consolidated entity’s growth strategy.

Environmental regulation

The consolidated entity is not subject to any significant environment regulation under Australian Commonwealth or State Law, United States Federal or State law or the Netherlands Civil Code. Titomic Kinetic Fusion™ is a resource-efficient process that minimizes waste and energy consumption compared to traditional casting, forging, and welding. By enabling in-situ repair and life extension of high-value assets, the technology reduces the carbon footprint associated with replacement manufacturing and logistics. The Board recognizes the importance of ESG considerations, and the consolidated entity’s technology inherently supports sustainability outcomes for customers and industries worldwide.

Material business risks

There are material business risks and uncertainties that have the potential to impact the future prospects of the consolidated entity. These risk factors and other general risks applicable to all investments in listed securities may affect the value of the securities in the future. An investment in the consolidated entity should be considered speculative. Investors may lose some or all of their investment.

A list of the key risk factors affecting the consolidated entity is provided below. The occurrence of any one of the risks below could adversely impact the consolidated entity’s operating and financial performance and prospects.

Failure to attract new customers

The success of the consolidated entity’s business relies on its ability to attract new business from existing customers and attract new customers across the regions where it operates. The capacity to attract new customers and attract new business from existing customers will be dependent on many factors including the capability, cost-effectiveness and value of the consolidated entity’s products and services compared to competing technologies. If the consolidated entity fails to execute on its business strategy, its business, financial condition and results of operations could be materially and adversely affected. This risk is expected to reduce as the consolidated entity advances current programs to pilot and production phases.

Product quality and manufacturing
Risks are involved in the ability to translate customer technical objectives into a solution that provides the expected quality of product in a cost-effective manner. The products and technology supplied by the consolidated entity may not be functional or not meet customers' expectations. This may lead to requirements for the consolidated entity to improve or refine its products, which may diminish operating margins or lead to losses. The products and technology supplied by the consolidated entity, while extensively tested prior to collection, can be damaged in transit. While this risk is insurable, it may diminish operating margins. Some solutions in development need further qualification and testing to achieve required certification levels or may not be developed in a timely manner which could negatively impact the consolidated entity's financial performance. This risk is not expected to impact financial performance as the consolidated entity is undertaking various certification and improvement programs that will help mitigate this risk.

Regulation and compliance
The consolidated entity is subject to regulation relating to export control compliance and quality regulations applicable to the manufacture of its products and various reporting regulations. There can be no guarantee that the regulatory environment in which the consolidated entity or its customers currently operates may not change in the future which may impact on the consolidated entity's existing products. Depending upon the severity of any failure of the consolidated entity or its customers to comply with any applicable regulations, the consolidated entity or its customers could be subject to enforcement actions. If any such actions are imposed against the consolidated entity they could harm the consolidated entity's reputation, and depending upon the severity, could have significant adverse impact upon the consolidated entity's ability to provide services and on its financial condition. The consolidated entity continues to ensure it has appropriate in-house and external knowledge in this area to mitigate against this risk having a material impact on financial results.

Supply chain
The consolidated entity sources certain key components for its systems from third party suppliers. The delivery of such components may be delayed, or a specific supplier may not be able to deliver at all, which may lead to a longer sales cycle. The goods received may not meet the specifications requested or be of the appropriate quality which may also lead to a longer sales cycle. Mitigation approached include quality assurance testing and multiple supplier arrangements to enable a shift to another supplier when and if required. In relation to metal powders, a key component, the consolidated entity has contractual arrangements with many of the key global powder suppliers to help ensure consistent and timely supply.

Currency
With operations in USA, Europe and Australia, the consolidated entity is exposed to foreign exchange risk from currency exposure due to fluctuations and volatility in exchange rates. In particular, while the consolidated entity continues to be in a pre-cash flow positive phase, it is difficult to hedge against this foreign exchange exposure other than by having bank accounts in, and holding cash balances in, the countries in which the consolidated entity operates to form a natural hedge for part of the currency risk exposure. Exchange rate fluctuations or volatility could have an adverse effect on the consolidated entity's future financial performance and position. Foreign currency risk will remain greater until the business is cash flow positive so the consolidated entity doesn't expect any changes to this risk in the short-term.

Key personnel
The consolidated entity's operational success will substantially depend on the continued employment of key executives, technical staff and other key personnel who have substantial strategic, technical, functional, marketing and customer expertise and who are well versed in the consolidated entity's technology, business and structure. Although these individuals have entered into contracts with the consolidated entity, there is no assurance that such contracts will not be terminated. If such contracts are terminated or breached, or if these individuals no longer continue in their current roles, new personnel will need to be employed, which in some cases, may adversely affect the business. The consolidated entity is substantially dependent on the continued service of its existing key personnel because of the complexity of its services and technologies. The departure of certain key personnel may also lead to disruptions of customer relationships or delays in the manufacturing and product development efforts. There is no assurance that the consolidated entity will be able to retain the services of these persons indefinitely. The consolidated entity mitigates against this risk by building a positive global workplace culture, developing a leadership succession plan, and ensuring its remuneration framework is competitive.

Technological development
The consolidated entity is currently investing into new research and development initiatives and new technologies. While the consolidated entity is not presently aware of any potential problems, the commerciality of new technologies and products based on innovative and new technology is uncertain. There are no guarantees that the outcomes of the research and development by the consolidated entity will be successful. Failure to effectively manage and oversee critical research and development, anticipate technical problems, or estimate research and development costs or timeframes accurately may adversely affect the consolidated entity's results and viability. This risk is expected to diminish over the next two years as the consolidated entity has employed key materials experts and engineers across its global workforce.

Information security
The consolidated entity is continuously strengthening its cyber and digital health to address the growing demand and requirements for information security in its clientele. In particular, defense and aerospace customers possess high value and confidential information which shall have significant impact on businesses and governments from both economical and geopolitical standpoints. The consolidated entity might be privileged to this information via commercial contracts with said customers. Depending on the level of sensitivity of the information provided, the consolidated entity shall ensure measures are in place so that only appropriate personnel have access to certain information, communications are encrypted properly and cyber attack threats are kept at a minimum. The consolidated entity has appropriate skills within its management team to address this risk, has incorporated cyber maturity tools and frameworks, and partnered with various government security agencies globally.

Government contracts
A portion of the consolidated entity's revenues may depend on the consolidated entity's ability to do business with the USA, Australian, Netherlands as well as other foreign governments and their various agencies, whether directly or indirectly. Such customers may:
• Award or terminate contracts at their convenience;
• Terminate, reduce or modify contracts or subcontracts if its requirements or budgetary constraints change;
• Cancel multi-year contracts and related orders if funds become unavailable;
• Shift their spending priorities, adjust contract costs and fees on the basis of audits done by its agencies;
• Use intellectual property developed in the performance of a government contract or subcontract and/or, claim rights to intellectual property not properly protected pursuant to applicable contract terms;
• Seek penalties and fines exceeding the value of a contract for contract activity that results in the submission of a false claim to the government;
• Debar the consolidated entity or its subsidiaries because of legal and other actions undertaken by or against the consolidated entity, the consolidated entity's officers, directors, shareholders, employees and affiliates, or convictions of the consolidated entity's officers, directors, shareholders, employees or affiliates;
• Inquire about and investigate business practices and audit compliance with applicable rules and regulations.
The consolidated entity has appropriate skills within its board of directors, senior management and legal counsel to help mitigate this risk.

Product liability and warranty
The consolidated entity's products are subject to customers' manufacturing standards. There is a risk that the consolidated entity's products may have actual or perceived safety or quality failures or defects which could result in: (a) litigation or claims alleging negligence, product liability or breach of warranty against the consolidated entity; (b) regulatory action; (c) damage to the consolidated entity's brand and reputation; and/or (d) the consolidated entity being forced to terminate or delay sales or operations. Despite best practice by the consolidated entity with respect to the manufacture and supply of its products and any insurance that the consolidated entity may hold, the risk of defective products remains and may negatively impact the consolidated entity's reputation, operations and financial prospects. This risk has been historically low and is expected to remain low as each global location ensures appropriate certification of its manufacturing procedures.

Titomic Limited
Directors' Report
For the six months ended 31 December 2025

Information on Directors, Company Secretary and Chief Financial Officer

The listed directorships, special responsibilities and shareholdings of each person who has been a Director of the consolidated entity at any time during or since 1 July 2025 is provided below, together with details of the Company Secretary and the Chief Financial Officer as at year end.

Name and title:	**Mr Dag W.R. Stromme** (Executive Chair)
Other current listed directorships:	None
Former directorships (last three years):	None
Membership of committees:	Audit and Risk Committee member, Remuneration and Nomination Committee
Interest in shares:	30,588,441 shares
Interest in rights and options:	52,734,375 options

Name and title:	**Mr Humphrey Nolan** (Independent Non-Executive Director)
Other current listed directorships:	None
Former directorships (last three years):	None
Membership of committees:	Audit and Risk Committee Chair, Remuneration and Nomination Committee Chair
Interest in shares:	53,230,000 shares
Interest in rights and options:	Nil

Name and title:	**Dr Andreas Schwer** (Independent Non-Executive Director)
Other current listed directorships:	Managing Director - Electro Optic Systems Limited (ASX:EOS) (appointed 11 December 2023)
Former directorships (last three years):	None
Membership of committees:	None
Interest in shares:	30,215,384 shares
Interest in rights and options:	Nil

Name and title:	**The Honorable Mira Ricardel** (Independent Non-Executive Director)
Other current listed directorships:	Proxy Board Director, Astroscale, U.S., Subsidiary of Astroscale Holding, Japan (listed on the JPX)
Former directorships (last three years):	None
Membership of committees:	None
Interest in shares:	216,154 shares
Interest in rights and options:	30,000,000 options

Name and title:	**Mr John Frewen AO, DSC** (Independent Non-Executive Director) (appointed 1 July
Other current listed directorships:	None
Former directorships (last three years):	None
Membership of committees:	Audit and Risk Committee member, Remuneration and Nomination Committee
Interest in shares:	80,000 shares
Interest in rights and options:	5,000,000 options

Name and title:	**Mr Richard Willson** (Independent Non-Executive Director) (resigned 1 July 2025)
Other current listed directorships:	None
Former directorships (last three years):	None
Membership of committees:	Audit and Risk Committee member, Remuneration and Nomination Committee

Mr Willson was no longer a key management personnel as of 31 December 2025 therefore his interests in shares, options and rights are not shown.

Name and title:	**Mr Jim Simpson** (Managing Director)
Other current listed directorships:	None
Former directorships (last three years):	None
Membership of committees:	None
Interest in shares:	6,204,518 shares
Interest in rights and options:	25,000,000 options

Name and title:	**Mr Geoff Hollis** (Chief Financial Officer and Company Secretary)
Other current listed directorships:	None
Former directorships (last three years):	None
Membership of committees:	None
Interest in shares:	Nil
Interest in rights and options:	6,900,000 options

Other current listed directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

Former directorships (last three years)' quoted above are directorships held in the last three years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

Meetings of directors

The number of meetings of the Company's Board of Directors ('the Board') and of each Board committee held during the six months ended 31 December 2025, and the number of meetings attended by each director were:

	Board		**Audit & Risk Committee**		**Remuneration and Nomination Committee**	
	No. of meetings eligible to attend	Attended	No. of meetings eligible to attend	Attended	No. of meetings eligible to attend	Attended
Mr Dag W.R. Stromme	6	6	2	2	1	1
Mr Humphrey Nolan	6	6	2	2	1	1
Mr Andreas Schwer	6	3	-	-	-	-
Ms Mira Ricardel	6	5	1	1	-	-
Mr John Frewen, AO, DSC	6	6	2	2	1	1
Mr Richard Willson	-	-	-	-	-	-
Mr Jim Simpson	6	5	-	-	-	-

Remuneration Report (audited)

The remuneration report details the key management personnel remuneration (KMP) arrangements for the consolidated entity, in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including all directors.

The Directors present the Titomic Limited Remuneration Report for the six months ended 31 December 2025, outlining key aspects of our remuneration policy and framework and remuneration awarded this year to Titomic Limited’s Executive Directors, Non-Executive Directors and other Key Management Personnel.

The remuneration report is set out under the following main headings:

- Principles used to determine the nature and amount of remuneration;
- Details of remuneration;
- Service agreements;
- Number of ordinary shares held by key management personnel;
- Options and performance rights to key management personnel; and
- Additional information.

Principles used to determine the nature and amount of remuneration

a) The objective of the consolidated entity's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:

- Having strategic objectives as a core component of the reward framework design;
- Focusing on sustained growth in shareholder wealth, which may comprise growth in share price, increasing opportunities for the consolidated entity as well as focusing the executive on key non-financial drivers of value;
- Alignment of executive compensation to performance; and
- Acceptability to shareholders.

b) The performance of the consolidated entity depends on the quality of its directors and executives. The remuneration philosophy is to attract, motivate and retain high performance and high-quality personnel. Accordingly, the reward framework should seek to enhance executives' interests by:

- Rewarding capability and application of relevant experience;
- Being competitive and providing a reasonable framework with regard to applicable industry standards;
- Reflecting competitive rewards for contribution to growth in shareholder wealth; and
- Providing a clear and transparent structure for earning rewards.

The Remuneration and Nomination Committee reviews, recommends and reports to the Board on remuneration and performance appraisal policies and practices.

In accordance with best practice corporate governance, the structure of non-executive director and executive director remuneration are treated separately.

Non-executive director's remuneration

Fees and payments to non-executive directors reflect the demands and responsibilities of their role. Non-executive directors' fees and payments are reviewed annually by the Board. The Board may, from time to time, receive advice from independent remuneration consultants to ensure non-executive directors' fees and payments are appropriate and in line with applicable industry standards.

ASX listing rules require the aggregate non-executive director’s remuneration be determined periodically by a general meeting. At the 2018 Annual General Meeting, the non-executive directors cash related fee pool was approved at $600,000.

Executive remuneration
The consolidated entity aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components.

The executive remuneration and reward framework has following components:
- Base pay and non-monetary benefits;
- Short-term performance incentives;
- Long-term performance incentives; and
- Other remuneration such as superannuation and leave.

The combination of these components comprises the executive's total remuneration.

The objective of the consolidated entity's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of the reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:
- competitiveness and reasonableness;
- acceptability to shareholders;
- performance linkage / alignment of executive compensation; and
- transparency.

The CEO consults with the Remuneration and Nomination Committee in relation to executive remuneration. Executive fixed remuneration, consisting of base salary and non-monetary benefits, are reviewed annually based on individual and business performance, the overall performance of the consolidated entity and comparable market remunerations.

The short-term incentives ('STI') program is designed to align the targets of the business units with the performance hurdles of executives. STI payments are granted to executive directors and executives based on specific annual targets and key performance indicators ('KPI's') being achieved. KPI's are determined by the Nomination and Remuneration Committee.

The long-term incentives ('LTI') include long service leave and share-based payments. Share rights and options are awarded to executives over longer-term periods based on long-term incentive measures (including share price performance and additional tenure). These are aligned to the increase in shareholders' value.

The Board has aligned short-term and long-term incentive structures with shareholder outcomes. Key metrics include revenue growth, gross margin expansion, contract wins with Tier One primes, and progress toward breakeven. Equity-based incentives are tied to sustained financial performance, ensuring management interests remain aligned with long-term shareholder value creation.

Consolidated entity performance and link to remuneration
Remuneration for certain individuals is directly linked to the role of the individual and the performance of the consolidated entity. A portion of cash bonus and incentive payments are dependent on defined targets being met. The remaining portion of the cash bonus and incentive payments are at the discretion of the Nomination and Remuneration Committee.

Refer to the section 'Additional information' below for details of the earnings and total shareholders' return for the last five years.

Details of remuneration

Details of the remuneration of key management personnel (KMP) of the consolidated entity are set out in the following tables.

	Short-term benefits			Post-employment benefits	Long-term benefits		
Six months ended 31 December 2025	**Cash salary, bonus and fees**	**Non-monetary benefits**	**Annual leave**	**Super-annuation**	**Long service leave**	**Share-based payments expense**	**Total**
	$	$	$	$	$	$	$
Non-Executive Directors							
Humphrey Nolan	37,500	-	-	-	-	90,177	127,677
Andreas Schwer	22,500	-	-	-	-	51,530	74,030
Mira Ricardel	23,750	-	-	-	-	51,530	75,280
John Frewen[(1)]	37,500	-	-	-	-	17,185	54,685
Richard Willson[(2)]	-	-	-	-	-	-	-
Executive Directors							
Dag W.R. Stromme	137,500	-	-	-	-	90,177	227,677
Jim Simpson[(3)(4)(5)]	524,417	88,765	29,662	19,073	-	199,714	861,631
Other Key Management Personnel							
Geoff Hollis	160,000	-	615	15,000	425	772,095	948,135
Patricia Dare[(6)(7)]	351,008	34,380	28,615	14,591	-	594,541	1,023,135
Klaas Rozema[(8)]	156,321	-	15,007	24,346	-	788,033	983,707
Aude Vignelles[(9)]	62,772	-	1,194	7,500	45	-	71,511
Total	**1,513,268**	**123,145**	**75,093**	**80,510**	**470**	**2,654,982**	**4,447,468**

Share-based payments expense include rights and options issued to Directors approved by shareholders at the Annual General Meetings held on 23 November 2023 and 25 November 2025 as well as rights and options issued to key management personnel on 16 July 2025.

(1) Mr Frewen was appointed as Non-Executive Director on 1 July 2025.

(2) Mr Willson resigned as Non-Executive Director on 1 July 2025.

(3) Included in Mr Simpson's remuneration were $214,564 cash bonus and $213,197 share-based payments expense (804,518 shares issued) following him achieving STI targets for the six months ending 31 December 2025.

(4) Included in Mr Simpson's share-based payments expense are $52,523 of reversed expenses related to the issue of 5,000,000 rights pursuant to his executive employment agreement. The expense was accrued and reported at a higher value in the prior period pending shareholders approval at the 2025 AGM.

(5) Included in Mr Simpson's share-based payments expense were $39,040 of expenses related to the issue of 25,000,000 options as long term incentive pursuant to his executive employment agreement. The expense was accrued and reported at a higher value in the prior period pending shareholders approval at the 2025 AGM. This has been partly reversed leading to a lower expense this

(6) Included in Ms Dare's remuneration were $48,396 cash bonus and $47,285 share-based payment expense (197,021 shares issued) in relation to her achieving STI targets for the six months ending 31 December 2025.

(7) Included in Ms Dare's share-based payments expense were $222,959 of expenses related to the issue of 2,321,429 rights pursuant to her executive employment agreement.

(8) Included in Mr Rozema's share-based payments expense were $116,647 of expenses related to the issue of 276,123 shares and (552,246 rights) following successful expansion of new manufacturing facility in Heerenveen, The Netherlands.

(9) Ms Vignelles became KMP as President, APAC (Titomic Limited) on 21 October 2025.

Titomic Limited
Directors' Report
For the six months ended 31 December 2025

	Short-term benefits			**Post-employment benefits**	**Long-term benefits**		
12 months ended 30 June 2025	**Cash salary, bonus and fees**	**Non-monetary benefits**	**Annual leave**	**Super-annuation**	**Long service leave**	**Share-based payments expense**	**Total**
	$	$	$	$	$	$	$
Non-Executive Directors							
Humphrey Nolan	66,452	-	-	-	-	328,758	395,210
Andreas Schwer	40,625	-	-	-	-	187,861	228,486
Mira Ricardel	40,625	-	-	-	-	187,861	228,486
Richard Willson(1)(2)	45,000	-	-	5,175	-	(23,262)	26,913
Executive Directors							
Dag W.R. Stromme(3)	212,292	-	-	-	-	328,758	541,050
Jim Simpson(4)(5)(6)	439,123	177,400	26,148	21,956	-	3,661,906	4,326,533
Herbert Koeck(7)(8)(9)	562,841	-	-	26,324	-	(927)	588,238
Other Key Management Personnel							
Geoff Hollis	320,000	-	(4,923)	29,932	762	41,962	387,733
Patricia Dare(10)(11)	333,986	35,821	21,286	11,847	-	535,359	938,299
Klaas Rozema(12)	288,902	-	23,140	44,352	-	18,668	375,062
Christopher Healy(13)	150,451	-	-	12,478	(6,515)	-	156,414
Total	**2,500,297**	**213,221**	**65,651**	**152,064**	**(5,753)**	**5,266,944**	**8,192,424**

Share-based payments expense for Directors include expenses in relation to rights and options approved by shareholders at the Annual General Meeting held on 23 November 2023.

(1) Mr Willson resigned as Non-Executive Director on 1 July 2025.

(2) Included in Mr Willson's share-based payments expense were reversed expenses for forfeited rights totalling $178,236.

(3) Mr Stromme commenced as Executive Chairman in October 2024.

(4) Mr Simpson commenced as President of Titomic USA, Inc. on 1 October 2024 and transitioned to CEO on 1 January 2025 and was appointed as Managing Director on 10 January 2025.

(5) Included in Mr Simpson's share-based payments expense are $1,027,523 of expenses related to the proposed issue of 5,000,000 rights as sign on bonus pursuant to his executive employment agreement, subject to shareholder approval at the 2025 AGM.

(6) Included in Mr Simpson's share-based payments expense were $2,634,383 of expenses related to the proposed issue of 25,000,000 options as long term incentive pursuant to his executive employment agreement, subject to shareholder approval at

(7) Mr Koeck retired as Managing Director and CEO on 31 December 2024.

(8) Included in Mr Koeck's remuneration was a six month notice payment plus post employment benefits.

(9) Included in Mr Koeck's share-based payments expense were reversed expenses for forfeited options totalling $148,523.

(10) Ms Dare became KMP as President, USA (Titomic USA Inc.) on 1 January 2025.

(11) Included in Ms Dare's share-based payments expense were $218,112 of expenses related to the issue of 2,321,429 rights as sign on bonus upon execution of her executive employment agreement

(12) Mr Rozema is a KMP since 1 July 2024 and is President of Titomic Europe B.V..

(13) Mr Healy retired as Legal Counsel and Company Secretary on 31 January 2025.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

	Fixed remuneration		**At risk - STI**		**At risk - LTI**	
	Six months ended 31-Dec-25	**12 months ended** 30-Jun-25	**Six months ended** 31-Dec-25	**12 months ended** 30-Jun-25	**Six months ended** 31-Dec-25	**12 months ended** 30-Jun-25
Non-Executive Directors						
Humphrey Nolan	29%	17%	-	-	71%	83%
Andreas Schwer	30%	18%	-	-	70%	82%
Mira Ricardel	32%	18%	-	-	68%	82%
John Frewen	69%	-	-	-	31%	-
Richard Willson	-	186%	-	-	-	(86%)
Executive Directors						
Dag W.R. Stromme	60%	39%	-	-	40%	61%
Jim Simpson	52%	15%	50%	-	(2%)	85%
Herbert Koeck	-	100%	-	-	-	(0%)
Other Key Management Personnel						
Geoff Hollis	19%	89%	-	-	81%	11%
Patricia Dare	37%	43%	9%	-	53%	57%
Klaas Rozema	20%	95%	-	-	80%	5%
Aude Vignelles	100%	-	-	-	-	-
Christopher Healy	-	100%	-	-	-	-

Service agreements

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name:	Mr Jim Simpson
Title:	CEO and Managing Director
Agreement commenced:	18 November 2024 (with recognition of remuneration from 1 October 2024)
Term of agreement:	On going
Details:	- Base salary is USD 375,000.
	- Monthly reimbursements up to USD 9,750 per month for insurance and housing.
	- Eligible for annual STI as determined by the Board no more than 100% of base salary with payment in cash and shares.
	- 5,000,000 sign-on rights awarded as an STI.
	- 25,000,000 options awarded as an LTI.
	- at will employment and 12 month post employment restraint.

Name:	Mr Geoff Hollis
Title:	Chief Financial Officer and Company Secretary
Agreement commenced:	13 May 2024
Term of agreement:	Ongoing
Details:	- Base salary is AUD 320,000 plus statutory superannuation.
	- Eligibility to participate in STI program up to 20% of base salary.
	- 6,900,000 options awarded as an LTI.
	- 3 month notice period and 12 month post employment restraint.

Name:	Dr Patricia Dare
Title:	President, USA
Agreement commenced:	1 January 2025
Term of agreement:	Ongoing
Details:	- Base salary is USD 362,500
	- Monthly reimbursements up to USD 3,750 per month for insurance.
	- Eligible for annual STI as determined by the Board no more than 50% of base salary with payment in cash and shares.
	- 2,321,429 sign-on rights awarded as an STI (allotted after 12 months service).
	- 11,607,143 options awarded as an LTI.
	- at will employment and 12 month post employment restraint.

Name:	Mr Klaas Rozema
Title:	President, EMEA
Agreement commenced:	1 December 2021
Term of agreement:	Mr. Rozema is commencing a six month sabbatical in March 2026 and will return as an advisor under a new agreement.
Details:	- Base salary is EUR 174,176 plus statutory pension and company car.
	- 6,000,000 options awarded as an LTI.
	- 1 month notice period and 12 month post employment restraint.

Name:	Ms Aude Vignelles
Title:	President, APAC
Agreement commenced:	21 October 2025
Term of agreement:	Ongoing
Details:	- Base salary is AUD 315,000 plus statutory superannuation.
	- Eligibility to participate in STI program up to 50% of base salary with payment in cash and shares.
	- Eligible for 1,750,000 rights as an LTI subject to probation.
	- Eligible for 5,700,000 options as an LTI subject to probation.
	- 3 month notice period and 12 month post employment restraint.

Number of ordinary shares held by key management personnel

Six months ended 31 December 2025		Balance at the start of the year	Balance at the appointment date	Granted as comp-ensation	Net changes (other)	Adjustment	Balance at the end of the year
Non-Executive Directors							
Humphrey Nolan[(1)(2)]		17,830,000	-	-	35,400,000	-	53,230,000
Andreas Schwer[(1)]		10,215,384	-	-	20,000,000	-	30,215,384
Mira Ricardel[(2)]		96,154	-	-	120,000	-	216,154
John Frewen[(2)]		-	-	-	80,000	-	80,000
Richard Willson[(3)]		12,620,000	-	-	-	(12,620,000)	-
Executive Directors							
Dag W.R. Stromme[(2)]		30,188,441	-	-	400,000	-	30,588,441
Jim Simpson[(2)(4)(5)]		-	-	804,518	5,400,000	-	6,204,518
Other Key Management Personnel							
Geoff Hollis		-	-	-	-	-	-
Patricia Dare[(6)]		-	-	-	-	-	-
Klaas Rozema[(7)]		3,102,160	-	276,123	-	-	3,378,283
Aude Vignelles		-	-	-	-	-	-
Total		**74,052,139**	**-**	**1,080,641**	**61,400,000**	**(12,620,000)**	**123,912,780**

Issue of shares to key management personnel

(1) Net changes other as a results of the vesting of rights for Mr Nolan (35,000,000 rights) and Mr Schwer (20,000,000 rights).

(2) Net changes other as a results of July 2025 placement share purchases, approved by shareholders at the 2025 AGM for Mr Nolan (400,000 shares), Ms Ricardel (120,000 shares), Mr Frewen (80,000 shares), Mr Stromme (400,000 shares) and Mr Simpson (400,000 shares).

(3) Mr Willson resigned effective 1 July 2025 therefore no balances are reflected at year end.

(4) Mr Simpson was issued 804,518 shares in relation to him achieving STI targets for the six months ending 31 December 2025.

(5) Mr Simpson was issued 5,000,000 shares as a result of the vesting of 5,000,000 rights after shareholder approval at the 2025 AGM.

(6) Ms Dare was issued 197,021 shares in relation to her achieving STI targets for the six months ending 31 December 2025.

(7) Mr Rozema was issued 276,123 shares following successful expansion of new manufacturing facility in Heerenveen, The Netherlands.

Options and performance rights to key management personnel

Options

The terms and conditions of each grant of options over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or future reporting years are as follows:

Name	Number of options granted	Grant date	Vesting and exercisable date	Expiry date	Hurdle price (15-day VWAP)	Fair value per option at grant date	Exercise price
Dag Stromme	17,500,000	4-Dec-23	4-Dec-24	4-Dec-26	$ 0.030	$ 0.015	-
Dag Stromme	17,500,000	4-Dec-23	4-Dec-25	4-Dec-27	$ 0.050	$ 0.014	-
Dag Stromme	17,500,000	4-Dec-23	4-Dec-25	4-Dec-27	$ 0.070	$ 0.012	-
Dag Stromme[(1)]	234,375	8-May-23	8-May-23	8-May-26	-	-	-
Mira Ricardel	10,000,000	4-Dec-23	4-Dec-24	4-Dec-26	$ 0.030	$ 0.015	-
Mira Ricardel	10,000,000	4-Dec-23	4-Dec-25	4-Dec-27	$ 0.050	$ 0.014	-
Mira Ricardel	10,000,000	4-Dec-23	4-Dec-25	4-Dec-27	$ 0.070	$ 0.012	-
John Frewen[(2)]	1,250,000	25-Nov-25	19-Dec-26	19-Dec-33	$ 0.440	$ 0.189	-
John Frewen[(2)]	1,750,000	25-Nov-25	19-Dec-27	19-Dec-34	$ 0.770	$ 0.186	-
John Frewen[(2)]	2,000,000	25-Nov-25	19-Dec-28	19-Dec-35	$ 1.000	$ 0.186	-
Jim Simpson[(3)]	5,000,000	25-Nov-25	18-Nov-25	18-Nov-32	$ 0.150	$ 0.195	-
Jim Simpson[(3)]	10,000,000	25-Nov-25	18-Nov-26	18-Nov-33	$ 0.180	$ 0.195	-
Jim Simpson[(3)]	10,000,000	25-Nov-25	18-Nov-27	18-Nov-34	$ 0.300	$ 0.163	-
Geoff Hollis	2,300,000	18-Jun-25	31-Dec-25	18-Jun-32	$ 0.330	$ 0.222	-
Geoff Hollis	2,300,000	18-Jun-25	31-Dec-26	18-Jun-32	$ 0.440	$ 0.238	-
Geoff Hollis	2,300,000	18-Jun-25	31-Dec-27	18-Jun-32	$ 0.770	$ 0.235	-
Patricia Dare	2,321,429	1-Jan-25	31-Dec-25	31-Dec-32	$ 0.330	$ 0.080	$ 0.220
Patricia Dare	4,642,857	1-Jan-25	31-Dec-26	31-Dec-33	$ 0.440	$ 0.110	$ 0.220
Patricia Dare	4,642,857	1-Jan-25	31-Dec-27	31-Dec-34	$ 0.770	$ 0.130	$ 0.220
Klaas Rozema	2,000,000	18-Jun-25	31-Dec-25	18-Jun-32	$ 0.330	$ 0.222	-
Klaas Rozema	2,000,000	18-Jun-25	31-Dec-26	18-Jun-32	$ 0.440	$ 0.238	-
Klaas Rozema	2,000,000	18-Jun-25	31-Dec-27	18-Jun-32	$ 0.770	$ 0.235	-

Options granted carry no dividend or voting rights.

(1) Mr Stromme's 234,375 options are related to his participation in 5 December 2022 placement, which were approved by shareholders at the 2023 Extraordinary General Meeting.

(2) Mr Frewen's 5,000,000 options were approved by shareholders at the 2025 AGM.

(3) Mr Simpson's 25,000,000 options were approved by shareholders at the 2025 AGM.

Titomic Limited
Directors' Report
For the six months ended 31 December 2025

The number of options over ordinary shares held by key management personnel are as follows:

Six months ended 31 December 2025	Balance at the start of the year	Additions	Vested/ lapsed/ cancelled/ other	Balance at the end of the year
Non-Executive Directors				
Humphrey Nolan	-	-	-	-
Andreas Schwer	-	-	-	-
Mira Ricardel	30,000,000	-	-	30,000,000
John Frewen	-	5,000,000	-	5,000,000
Richard Willson	-	-	-	-
Executive Directors				
Dag W.R. Stromme	52,734,375	-	-	52,734,375
Jim Simpson	25,000,000	-	-	25,000,000
Other Key Management Personnel				
Geoff Hollis	6,900,000	-	-	6,900,000
Patricia Dare	11,607,143	-	-	11,607,143
Klaas Rozema	6,000,000	-	-	6,000,000
Aude Vignelles	-	-	-	-
Total	**132,241,518**	**5,000,000**	**-**	**137,241,518**

Performance rights
The terms and conditions of each grant of performance rights over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or future reporting are as follows:

Name	**Number of rights granted**	**Grant date**	**Vesting date**	**Expiry Date**	**Hurdle price (15-day VWAP)**	**Fair value per right at grant date**
Humphrey Nolan(1)	17,500,000	4-Dec-23	4-Dec-25	4-Dec-27	$ 0.05	$ 0.014
Humphrey Nolan(1)	17,500,000	4-Dec-23	4-Dec-25	4-Dec-27	$ 0.07	$ 0.012
Andreas Schwer(2)	10,000,000	4-Dec-23	4-Dec-25	4-Dec-27	$ 0.05	$ 0.014
Andreas Schwer(2)	10,000,000	4-Dec-23	4-Dec-25	4-Dec-27	$ 0.07	$ 0.012
Jim Simpson(3)	5,000,000	25-Nov-25	18-Nov-25	18-Nov-25	$ -	$ 0.195
Patricia Dare(4)	2,321,429	1-Jan-25	31-Dec-25	31-Dec-25	$ -	$ 0.190

Performance rights granted carry no dividend or voting rights.
(1) Mr Nolan's 35,000,000 rights vested and 35,000,000 shares were issued in December 2025 upon achieving vesting conditions.
(2) Mr Schwer's 20,000,000 rights vested and 20,000,000 shares were issued in December 2025 upon achieving vesting conditions.
(3) Rights for Mr Simpson were approved by shareholder at the 2025 AGM. Mr Simpson's 5,000,000 rights vested and 5,000,000 shares were issued in December 2025 upon achieving vesting conditions.
(4) Ms Dare's 2,321,429 rights vested upon achieving vesting condition in December 2025, and 2,321,429 shares were issued in January 2026.

The number of performance rights over ordinary shares held by key management personnel are as follows:

Six months ended 31 December 2025	Balance at the start of the year	Additions	Vested/ lapsed/ cancelled/ other	Balance at the end of the year
Non-Executive Directors				
Humphrey Nolan	35,000,000	-	(35,000,000)	-
Andreas Schwer	20,000,000	-	(20,000,000)	-
Mira Ricardel	-	-	-	-
John Frewen	-	-	-	-
Richard Willson	-	-	-	-
Executive Directors				
Dag W.R. Stromme	-	-	-	-
Jim Simpson	5,000,000	-	(5,000,000)	-
Other Key Management				
Geoff Hollis	-	-	-	-
Patricia Dare	2,321,429	-	-	2,321,429
Klaas Rozema	-	-	-	-
Aude Vignelles	-	-	-	-
Total	**62,321,429**	**-**	**(60,000,000)**	**2,321,429**

Additional information

The historical earnings of the Consolidated Entity are summarised below:

	Six months ended 31-Dec-25 $	**12 months ended 30-Jun-25 $**	**12 months ended 30-Jun-24 $**	**12 months ended 30-Jun-23 $**	**12 months ended 30-Jun-22 $**
Revenue	5,270,650	9,427,102	7,697,370	4,488,394	5,320,623
Net loss after tax	(17,851,299)	(19,886,876)	(11,892,164)	(15,709,484)	(16,971,886)
Total remuneration of KMP	4,447,468	8,192,424	4,716,371	2,439,859	3,756,876
Total performance-based remuneration	2,654,982	5,266,944	2,145,483	1,307,101	1,904,543

Note: total performance based remuneration for the 2024 financial year excludes expenses relating to cancellation of rights and options.

Increase / (decrease) in revenue (%)	(44%)	22%	71%	(16%)	168%
Change in share price (%)	(20%)	311%	265%	(93%)	(35%)

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

	31-Dec-25	**30-Jun-25**	**2024**	**2023**	**2022**
Share price - start of the financial year ($)	0.30	0.07	0.02	0.26	0.60
Share price - end of the financial year ($)	0.24	0.30	0.07	0.02	0.26
Basic earnings per share ($)	(0.0119)	(0.0164)	(0.0136)	(0.0698)	(0.0905)
Diluted earnings per share ($)	(0.0119)	(0.0164)	(0.0136)	(0.0698)	(0.0905)

Voting and comments made at the Company's 2025 Annual General Meeting

At the 2025 Annual General Meeting , 91.25% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2025. The consolidated entity did not receive any specific feedback at the Annual General Meeting regarding its remuneration practices.

This concludes the remuneration report, which has been audited.

Titomic Limited
Directors' Report
For the six months ended 31 December 2025

Shares under option
Unissued ordinary shares of Titomic Limited under option at the date of this report are as follows:

Grant date	Expiry date	Hurdle price	Exercise price	Number under option
8-May-23	8-May-26	$0.00	$0.40	22,312,500
4-Dec-23	4-Dec-26	$0.03	$0.00	50,800,000
4-Dec-23	4-Dec-27	$0.05	$0.00	27,500,000
4-Dec-23	4-Dec-27	$0.07	$0.00	27,500,000
18-Nov-24	18-Nov-32	$0.15	$0.00	5,000,000
18-Nov-24	18-Nov-33	$0.18	$0.00	10,000,000
18-Nov-24	18-Nov-34	$0.30	$0.00	10,000,000
1-Jan-25	31-Dec-32	$0.33	$0.22	4,642,858
1-Jan-25	31-Dec-33	$0.44	$0.22	9,285,714
1-Jan-25	31-Dec-34	$0.77	$0.22	9,285,714
21-Apr-25	21-Apr-33	$0.33	$0.22	1,250,000
21-Apr-25	21-Apr-34	$0.44	$0.22	2,500,000
21-Apr-25	21-Apr-35	$0.77	$0.22	2,500,000
20-Jun-25	20-Jun-33	$0.33	$0.22	250,000
20-Jun-25	20-Jun-34	$0.44	$0.22	500,000
20-Jun-25	20-Jun-35	$0.77	$0.22	500,000
18-Jun-25	18-Jun-32	$0.33	$0.00	4,405,000
18-Jun-25	18-Jun-32	$0.44	$0.00	4,405,000
18-Jun-25	18-Jun-32	$0.77	$0.00	4,405,000
25-Nov-25	19-Dec-33	$0.44	$0.00	1,250,000
25-Nov-25	19-Dec-34	$0.77	$0.00	1,750,000
25-Nov-25	19-Dec-35	$1.00	$0.00	2,000,000
				202,041,786

Performance rights outstanding
Performance rights outstanding for Titomic Limited as at the date of this report are as follows:

Grant date	Expiry date	Hurdle price	Exercise price	Number of rights
21-Apr-25	21-Apr-26	$0.00	$0.00	1,250,000
				1,250,000

Shares issued on the exercise of options
The following ordinary shares of Titomic Limited were issued during the prior year and up to the date of this report on the exercise of options.

Date shares issued	Exercise price	Number of shares issued
7-Oct-25	$0.0700	2,000,000
9-Jan-26	$0.0000	1,700,000

Indemnity and insurance of officers
The company has indemnified the directors and executives of the company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the company paid a premium in respect of a contract to insure the directors and executives of the company against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

Indemnity and insurance of auditor
The company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the company or any related entity against a liability incurred by the auditor.

During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company or any related entity.

Proceedings on behalf of the company
No person has applied to the Court under Section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or part of those proceedings.

Non-audit services
During the six months ended 31 December 2025, there was no non-audit services provided by the auditors.

Rounding of amounts
The company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors

Dag W.R. Stromme

Dag W.R. Stromme
Chair

27 February 2026

RSM Australia Partners

Level 27, 120 Collins Street Melbourne VIC 3000
PO Box 248 Collins Street West VIC 8007

T +61 (0) 3 9286 8000
F +61 (0) 3 9286 8199

www.rsm.com.au

AUDITOR'S INDEPENDENCE DECLARATION

As lead auditor for the audit of the financial report of Titomic Limited and its controlled entities for the six month period ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

(i) the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and

(ii) any applicable code of professional conduct in relation to the audit.

RSM AUSTRALIA PARTNERS

B Y CHAN
Partner

Date: 27 February 2026
Melbourne, Victoria

Titomic Limited
Consolidated Statement of Profit and Loss and Other Comprehensive Income
For the six months ended 31 December 2025

	Note	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Revenue			
Sales revenue	6	4,008,246	8,114,049
Other revenue	6	1,262,404	1,313,053
		5,270,650	**9,427,102**
Fair value adjustment	4	-	145,385
Expenses			
Production and related expenses		(6,977,975)	(8,297,785)
Corporate and administrative expenses		(9,418,307)	(11,161,085)
Sales, marketing and promotion expenses		(1,926,415)	(3,282,888)
Other expenses		(4,738)	(92,893)
Remuneration expense on Tri-D and Dycomet acquisition	8	-	(18,181)
Share based payments expenses	9	(3,667,145)	(6,026,275)
Depreciation expenses	7	(555,224)	(342,415)
Finance costs	7	(572,145)	(296,079)
		(23,121,949)	**(29,517,601)**
Loss before income tax expense		**(17,851,299)**	**(19,945,114)**
Income tax expense	10	-	58,238
Net Loss after Income Tax Expense		**(17,851,299)**	**(19,886,876)**
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation reserve	25	(200,199)	(554,215)
Income tax relating to these items		-	-
Other comprehensive loss, net of tax		(200,199)	(554,215)
Total comprehensive loss for the year Attributable to the Owners of Titomic Limited		**(18,051,498)**	**(20,441,091)**
		$	**$**
Basic earnings (loss) per share	11	(0.0119)	(0.0164)
Diluted earnings (loss) per share	11	(0.0119)	(0.0164)

These financial statements should be read in conjunction with the accompanying notes.

Titomic Limited
Consolidated Statement of Financial Position
As at 31 December 2025

	Note	31-Dec-25	30-Jun-25
		$	$
Current Assets			
Cash and cash equivalents	12	35,765,201	8,926,447
Trade and other receivables	13	1,554,880	351,612
Inventories	14	3,437,885	4,173,516
Contract assets	15	-	581,585
Other current assets	16	456,254	935,598
Income tax receivable		-	2,821
Total Current Assets		41,214,220	14,971,579
Non-Current Assets			
Property, plant and equipment	17	26,843,936	17,493,988
Right-of-use assets	18	2,460,769	2,603,574
Other non-current assets		30,897	30,897
Total Non-Current Assets		29,335,602	20,128,459
Total Assets		**70,549,822**	**35,100,038**
Current Liabilities			
Trade and other payables	19	3,492,580	3,564,257
Provisions	20	1,004,759	729,765
Borrowings	21	4,484,813	502,067
Lease liabilities	22	356,820	346,154
Other financial liabilities	23	794,981	2,250,697
Total Current Liabilities		10,133,953	7,392,940
Non-Current Liabilities			
Provisions	20	135,122	162,616
Borrowings	21	8,675,033	8,706,090
Lease liabilities	22	2,401,652	2,634,381
Other financial liabilities	23	1,398,193	1,388,964
Total Non-Current Liabilities		12,610,000	12,892,051
Total Liabilities		**22,743,953**	**20,284,991**
Net Assets		**47,805,869**	**14,815,047**
Equity			
Issued capital	24	72,655,460	23,130,710
Reserves	25	15,984,193	14,666,822
Accumulated losses	26	(40,833,784)	(22,982,485)
Total Equity		**47,805,869**	**14,815,047**

These financial statements should be read in conjunction with the accompanying notes.

Titomic Limited
Consolidated Statement of Changes in Equity
For the six months ended 31 December 2025

	Notes	Issued Capital $	Reserves $	Accumulated Losses $	Total Equity $
Balance as at 1 July 2024		75,211,575	10,417,654	(84,598,795)	1,030,434
Net loss after income tax		-	-	(19,886,876)	(19,886,876)
Other comprehensive loss after tax		-	(554,215)	-	(554,215)
Total comprehensive loss		-	(554,215)	(19,886,876)	(20,441,091)
Transactions with owners in their capacity as owners					
Contributions of equity	**24**	30,100,000	-	-	30,100,000
Costs of contributions of equity	**24**	(1,928,457)	-	-	(1,928,457)
Share based payments	**25**	1,250,778	4,803,383	-	6,054,161
Technical adjustment to share capital	**24**	(81,503,186)	-	81,503,186	-
Balance as at 30 June 2025		**23,130,710**	**14,666,822**	**(22,982,485)**	**14,815,047**

	Notes	Issued Capital $	Reserves $	Accumulated Losses $	Total Equity $
Balance as at 1 July 2025		23,130,710	14,666,822	(22,982,485)	14,815,047
Net loss after income tax		-	-	(17,851,299)	(17,851,299)
Other comprehensive loss after tax		-	(200,199)	-	(200,199)
Total comprehensive loss		-	(200,199)	(17,851,299)	(18,051,498)
Transactions with owners in their capacity as owners					
Contributions of equity	**24**	50,490,000	-	-	50,490,000
Costs of contributions of equity	**24**	(3,114,824)	-	-	(3,114,824)
Share based payments	**25**	2,149,574	1,517,570	-	3,667,144
Balance as at 31 December 2025		**72,655,460**	**15,984,193**	**(40,833,784)**	**47,805,869**

These financial statements should be read in conjunction with the accompanying notes.

Titomic Limited
Consolidated Statement of Cash Flows
For the six months ended 31 December 2025

	Note	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Cash Flows from Operating Activities			
Receipts from customers (inclusive of GST)		2,749,415	8,578,384
Payments to suppliers and employees (inclusive of GST)		(17,683,224)	(24,535,833)
Interest received		216,236	449,825
Interest and other finance costs paid		(443,971)	(106,914)
Income tax (paid) / refunded		2,800	(31,811)
Government grants and tax incentives		4,262	924,134
Rental income from U.S. premises		294,631	-
Net cash outflow from operating activities	**29**	**(14,859,851)**	**(14,722,215)**
Cash Flows from Investing Activities			
Payments for deferred consideration in relation to business acquisition		-	(263,935)
Payment for property, plant and equipment		(8,821,732)	(14,903,074)
Proceeds from / (payment for) other assets (security deposits)		-	124,888
Net cash outflow from investing activities		**(8,821,732)**	**(15,042,121)**
Cash Flows from Financing Activities			
Proceeds from the issue of shares	**24**	50,350,000	30,009,706
Proceeds from the exercise of options	**24**	140,000	100,000
Share issue transactions costs	**24**	(3,113,500)	(1,881,421)
Proceeds from borrowings	**22**	4,313,001	8,970,565
Repayment of borrowings		(351,664)	(531,232)
Payment for the principal portion of lease liabilities		(263,148)	(465,766)
Net cash inflow from financing activities		**51,074,689**	**36,201,852**
Net increase (decrease) in cash and cash equivalents		27,393,106	6,437,516
Cash and cash equivalents at start of period		8,926,447	2,729,484
Effects of exchange rate changes on cash and cash equivalents		(554,352)	(240,553)
Cash and cash equivalents at end of period	**12**	**35,765,201**	**8,926,447**

These financial statements should be read in conjunction with the accompanying notes.

1 Material accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

General information

The financial statements cover Titomic Limited as a consolidated entity consisting of Titomic Limited and the entities it controlled at the end of or during, the year. The financial statements are presented in Australian dollars, which is Titomic Limited's functional and presentation currency.

Titomic Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are Unit 1, 371 Ferntree Gully Road, Mount Waverley, Victoria 3149, Australia.

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, as of the date of the directors’ report. The directors have the power to amend and reissue the financial statements.

Change to the Financial Year

The consolidated entity elected to change its financial year end from 30 June to 31 December to align its reporting dates with its United States and Netherlands based subsidiaries. This financial report is for the 6 months ended 31 December 2025, with the comparative period being the 12 months ended 30 June 2025. As a result, the amounts presented in the consolidated financial statements are not directly comparable.

a) Basis of Preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the *Corporations Act 2001* , as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention

The financial statements have been prepared under the historical cost convention.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

Parent entity information

In accordance with the *Corporations Act 2001* , these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 33.

Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Titomic Limited ('Company' or 'parent entity') as at 31 December 2025 and the results of all subsidiaries for the year then ended. Titomic Limited and its subsidiaries together are referred to in these financial statements as the 'consolidated entity'.

1 Material accounting policies (continued)

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Comparatives
Comparative figures for the prior year have been re-classified where appropriate to align with current year disclosures.

b) Going Concern
The financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

As disclosed in the financial statements, the consolidated entity incurred a loss from ordinary activities of $17,851,299 during the 6 months ended 31 December 2025 (12 months ended 30 June 2025: $19,886,876loss) and had a net cash outflow from operating activities of $14,859,851 (12 months ended 30 June 2025: $14,722,215).

The Directors believe it is reasonably foreseeable that the consolidated entity will continue as a going concern and consider it appropriate to prepare the financial report on that basis, noting that the $50,000,000 capital raise completed in July 2025 (before costs) is expected to provide sufficient funding to support forecast cash flows and net outgoings.

c) Foreign currency translation
The financial statements are presented in Australian dollars, which is Titomic Limited's functional and presentation currency.

Foreign currency transactions
Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

Foreign operations
The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity.

The foreign currency reserve is recognised in profit or loss when the foreign operation or net investment is disposed of.

1 Material accounting policies (continued)

d) Revenue recognition

Revenue recognition

Revenue is measured at an amount that reflects the consideration to which the Consolidated entity expects to be entitled in exchange for the goods or services. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties.

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the consolidated entity: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability.

Manufacturing and sale of machines, projects and consumables

Revenue from the sale of goods, including consumables, spare parts and low-value systems, is recognised at the point in time when control passes to the customer, generally upon delivery.

Revenue from long-term projects, such as high-value bespoke systems, is recognised over time when the customer controls the asset as it is created, the Group's work is performed at the customer's site, and the Group has an enforceable right to payment for work completed to date. Progress is measured using a method that faithfully depicts performance to date.

Rental of machinery

Rental of machinery revenue is recognised as income in the period when earned.

Interest

Interest revenue is recognised using the effective interest rate method.

Grant revenue and Research & Development incentives

Government grants are recognised when they are received or when the right to receive payment is established. The Consolidated entity may undertake R&D activities under competitive grants and be part-funded by other incentive programs (for example R&D tax incentives). There is no certainty that grants or incentive programs will continue to be available to the Consolidated entity, and changes in government policy may reduce their applicability. R&D tax incentives are recorded as revenue when the company has determined that it has a valid claim.

1 Material accounting policies (continued)

Receivables from contracts with customers
A receivable from a contract with a customer represents the company's unconditional right to consideration arising from the transfer of goods or services to the customer (i.e., only the passage of time is required before payment of the consideration is due). Subsequent to initial recognition, receivables from contracts with customers are measured at amortised cost and are tested for impairment.

Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.

All revenue is measured net of the amount of Goods and Services Tax (GST).

e) Income tax
Current income tax expense or revenue is the tax payable on the current period's taxable income based on the applicable income tax rate adjusted by changes in deferred tax assets and liabilities.

Deferred tax assets and liabilities are recognised for temporary differences at the applicable tax rates when the assets are expected to be recovered or liabilities are settled. Deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction, other than a business combination, that at the time of the transaction affects neither accounting nor taxable profit or loss.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity.

f) Current and non-current classification
Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the consolidated entity's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

g) Inventories
Inventories including raw materials and consumables are valued using a standard costing method, which is reviewed and recalculated periodically on an annual or bi-annual basis. Standard costs include supplier's nominated prices or latest actual purchase cost and an additional proportion of anticipated in-bound freight or inventory handling costs. Quantitative movements are conducted and recorded on a first-in-first-out basis, incorporating standard costs to determine transactional financial values.

1 Material accounting policies (continued)

Inventories including finished goods and work in progress (WIP) are measured as a combination of value of raw materials consumed, direct labour costs assigned and appropriate allocation of overhead expenses.

h) Cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement of financial position.

i) Trade and other receivables

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit loss. Trade receivables are generally due for settlement within 30 days. See note 13 for further information about the consolidated entity's accounting for trade receivables.

The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

j) Property, plant and equipment

All property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. For capital work in progress (WIP), depreciation commences upon the asset becoming operational. For all other assets except land, depreciation commences upon the date of purchase.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the asset will flow to the consolidated entity and the cost of the asset can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Depreciation is calculated using the straight-line method of depreciation to allocate the cost or revalued amounts of the asset, net of the residual values, over the estimated useful life of the asset or, in the case of leasehold improvements and certain leased plant and equipment, the shorter lease term as follows:

Buildings	30 years
Building fit outs	Lesser of lease life or 10 years
Computer equipment & software	3 - 5 years
Factory equipment & machinery	3 - 10 years
Land	Not depreciated
Capital WIP	Not depreciated

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the consolidated entity. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss. Any revaluation surplus reserve relating to the item disposed of is transferred directly to retained profits.

1 Material accounting policies (continued)

k) Right-of-use assets

Right-of-use assets are measured at cost less depreciation and impairment and adjusted for any remeasurement of the lease liability.

The cost of the asset includes: the amount of the initial measurement of the lease liability; any lease payments made at or before lease commencement date less any lease incentives received; and initial direct costs; and present value of expected restoration costs.

Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term.

The consolidated entity tests right-of-use assets for impairment where there is an indicator that the asset may be impaired. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

The Consolidated entity determines the lease term as the non-cancellable period of a lease together with both: the periods covered by an option to extend the lease if it is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the lessee is reasonably certain not to exercise that option.

Management considers all the facts and circumstances that create an economic incentive to exercise an extension option or not exercise a termination option. This assessment is reviewed if a significant event or a significant change in circumstances occurs which affects this assessment and that is within the control of the lessee.

l) Trade and other payables

These amounts represent liabilities for goods and services provided to the consolidated entity prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

m) Borrowings

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

n) Lease liabilities

Lease liabilities are initially measured at the present value of the lease payments discounted using the interest rate implicit in the lease. If that rate cannot be determined, the consolidated entity's incremental borrowing rate is used.

Lease liabilities are subsequently measured by: increasing the carrying amount to reflect interest on the lease liabilities; reducing the carrying amount to reflect lease payments made; and remeasuring the carrying amount to reflect any reassessment or lease modifications.

Interest on the lease liabilities and any variable lease payments not included in the measurement of the lease liabilities are recognised in the Consolidated Statement of Profit or Loss and Comprehensive Income in the period in which they relate.

o) Finance costs

Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

1 Material accounting policies (continued)

p) Provisions

Provisions are recognised when the consolidated entity has a present (legal or constructive) obligation as a result of a past event, it is probable that the consolidated entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost.

q) Employee benefits

Short-term employee benefits

Liabilities arising in respect of wages and salaries, annual leave, and any other employee benefits (other than termination benefits) expected to be settled wholly before twelve months after the end of the annual reporting period are measured at the (undiscounted) amounts based on remuneration rates which are expected to be paid when the liability is settled. The expected cost of short-term employee benefits in the form of compensated absences such as annual leave is recognised in the provision for employee benefits. All other short-term employee benefit obligations are presented as payables in the statement of financial position.

Other long-term employee benefits

The provision for other long-term employee benefits, including obligations for long service leave and annual leave, which are not expected to be settled wholly before twelve months after the end of the reporting period, are measured at the present value of the estimated future cash outflow to be made in respect of the services provided by employees up to the reporting date. Expected future payments incorporate anticipated future wage and salary levels, durations of service and employee turnover, and are discounted at rates determined by reference to market yields at the end of the reporting period on high quality corporate bonds that have maturity dates that approximate the terms of the obligations. Any remeasurements for changes in assumptions of obligations for other long-term employee benefits are recognised in profit or loss in the periods in which the change occurs.

Other long-term employee benefit obligations are presented as current liabilities in the balance sheet if the consolidated entity does not have an unconditional right to defer settlement for at least twelve months after the reporting date, regardless of when the actual settlement is expected to occur. All other long-term employee benefit obligations are presented as non-current liabilities in the statement of financial position.

Defined contribution superannuation plan

The Company makes superannuation contributions (as per statutory rates) to the employee’s defined contribution superannuation plan of choice in respect of employee services rendered during the year.

These superannuation contributions are recognised as an expense in the same period when the related employee services are received. The Company’s obligation with respect to employee’s defined contributions entitlements is limited to its obligation for any unpaid superannuation guarantee contributions at the end of the reporting period.

All obligations for unpaid superannuation guarantee contributions are measured at the (undiscounted) amounts expected to be paid when the obligation is settled and are presented as current liabilities in the statement of financial position.

1 Material accounting policies (continued)

Share-based payments
Share-based compensation benefits may be provided through the issue of fully paid ordinary shares under the Employee Share and Option Plan. Options may also be granted to employees and consultants in accordance with the terms of their respective employment and consultancy agreements. Any options granted to employees are made in accordance with the terms of the consolidated entity's Employee Share and Option Plan (ESOP) and Employee Incentive Plan (EIP).

The fair value of options granted under employment and consultancy agreements are recognised as share based payment expenses with a corresponding increase in equity. The fair value of the options are measured at grant date and recognised over the period during which the employees or consultants become unconditionally entitled to the options.

The fair value of the options at grant date is determined using either Black Scholes or Monte Carlo method pricing model that takes into account the exercise price, the term of the option, the vesting and performance criteria, the impact of dilution, the non-tradeable nature of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option.

The fair value of any equity granted may include the impact of market (for example, share price target) and non-market vesting conditions (for example, profitability and sales growth targets). These vesting conditions are included in assumptions about the number of securities that are expected to be issued or become exercisable. At each reporting date, the entity assesses, and when necessary revises the estimated number of securities that are expected to be issued or become exercisable. The expense recognised each period takes into account the most recent estimate. The impact of any revision to original estimates is recognised in the statement of profit or loss and other comprehensive income with a corresponding adjustment to equity.

Upon the exercise of options, the balance of the share-based payments reserve relating to those options is transferred to contributed equity.

The cumulative charge to profit or loss until settlement of the liability is calculated as follows:
- during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period; and
- from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the consolidated entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the consolidated entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

1 Material accounting policies (continued)

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

r) Contract assets and liabilities

Contract assets

Contract assets are recognised when the consolidated entity has transferred goods or services to the customer but where the consolidated entity is yet to establish an unconditional right to consideration. Contract assets are treated as financial assets for impairment purposes.

Contract liabilities

Contract liabilities represent the consolidated entity's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration or when the consolidated entity recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the consolidated entity has transferred the goods or services to the customer.

s) Fair value measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests.

For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.

t) Issued capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

1 Material accounting policies (continued)

u) Earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to the owners of Titomic Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after-income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

v) Goods and Services Tax ('GST') and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

w) Rounding of amounts

The company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

x) New Accounting Standards and Interpretations not yet mandatory or early adopted

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 31 December 2025. The consolidated entity has not yet assessed the impact of these new or amended Accounting Standards and Interpretations.

AASB 18 Presentation and Disclosure in Financial Statements

This standard is applicable to annual reporting periods beginning on or after 1 January 2027 and early adoption is permitted. The standard replaces IAS 1 'Presentation of Financial Statements', with many of the original disclosure requirements retained and there will be no impact on the recognition and measurement of items in the financial statements. But the standard will affect presentation and disclosure in the financial statements, including introducing five categories in the statement of profit or loss and other comprehensive income: operating, investing, financing, income taxes and discontinued operations. The standard introduces two mandatory sub-totals in the statement: 'Operating profit' and 'Profit before financing and income taxes'. There are also new disclosure requirements for 'management-defined performance measures', such as earnings before interest, taxes, depreciation and amortisation ('EBITDA') or 'adjusted profit'. The standard provides enhanced guidance on grouping of information (aggregation and disaggregation), including whether to present this information in the primary financial statements or in the notes. The consolidated entity is expected to adopt this standard from 1 January 2027 and it is expected that there will be a significant change to the layout of the statement of profit or loss and other comprehensive income.

2 Critical Accounting Estimates, Assumptions and Judgements

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Research and development tax incentive
The consolidated entity adopts the income approach to accounting for the research and development tax incentive pursuant to AASB 120 'Accounting for Government Grants and Disclosure of Government Assistance'. The directors have concluded that the consolidated entity has developed sufficient systems and knowledge to allow reasonable assurance to be obtained with respect to the measurement and recognition of tax rebates at a point when they believe they have a valid claim. The claim incorporates estimates around R&D apportionment for certain shared assets (such as machines and employees) and judgements around the expense's eligibility under the Tax Incentive Application.

Share-based payment transactions
The consolidated entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by either Black Scholes or Monte-Carlo method pricing model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Provision for impairment of inventories
The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventories and other factors that affect inventory obsolescence.

Estimation of useful lives of assets
The consolidated entity determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other events. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Impairment of non-financial assets other than goodwill
The consolidated entity assesses the impairment of non-financial assets other than goodwill at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

Impairment of property, plant and equipment
The consolidated entity assesses impairment of property, plant and equipment at each reporting date by evaluating conditions specific to the consolidated entity and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

2 Critical Accounting Estimates, Assumptions and Judgements (continued)

Deferred consideration

The deferred consideration liability is the difference between the total purchase consideration, usually on an acquisition of a business combination, and the amounts paid or settled up to the reporting date, discounted to net present value. The consolidated entity applies provisional accounting for any business combination. Any reassessment of the liability during the earlier of the finalisation of the provisional accounting or 12 months from acquisition-date is adjusted for retrospectively as part of the provisional accounting rules in accordance with AASB 3 'Business Combinations'. Thereafter, at each reporting date, the deferred consideration liability is reassessed against revised estimates and any increase or decrease in the net present value of the liability will result in a corresponding gain or loss to profit or loss. The increase in the liability resulting from the passage of time is recognised as a finance cost.

Incremental borrowing rate implicit in lease arrangements

The incremental borrowing rate in the lease is for the purpose of lease classification and measurement. The interest rate 'implicit' in the lease is the discount rate and is used to sum of the present value of the lease payments for measurement purposes.

Lease term

The lease term is a significant component in the measurement of both the right-of-use asset and lease liability. Judgement is exercised in determining whether there is reasonable certainty that an option to extend the lease will be exercised, or an option to terminate the lease will not be exercised, when ascertaining the periods to be included in the lease term.

Contract assets and liabilities

Significant judgement is required in measuring contract assets and liabilities, particularly in assessing progress towards completion, estimating future costs to complete (including the impact of scope changes), and recognising obligations for maintenance and defect rectification. Judgement is also applied in assessing the likelihood and amount of performance bonuses or penalties. These estimates affect the timing and amount of revenue recognised and may result in gains or losses on individual contracts.

Contingent assets and liabilities

Contingent assets and liabilities are recognised or disclosed based on Management’s assessment of the probability of future events and the estimation of the potential financial impact of those events. These assessments are inherently uncertain and require significant judgment, particularly in relation to legal disputes, regulatory matters, tax positions and other claims. In assessing contingencies, Management considers all available information, including legal advice and, where appropriate, opinions from external experts. Actual outcomes may differ from Management’s estimates due to changes in facts, circumstances or interpretations of applicable laws and regulations. Such differences may result in material adjustments to the amounts recognised or disclosed in future periods.

3 Financial risk management

(a) Financial instruments

The consolidated entity's financial instruments consist of cash and cash equivalents, trade and other receivables and trade and other payables. Financial instruments are set out below:

	31-Dec-25	**30-Jun-25**
	$	**$**
Cash and cash equivalents	35,765,201	8,926,447
Trade and other receivables	1,554,880	351,612
Other current assets	456,254	935,598
Trade and other payables	3,492,580	3,564,257
Borrowings	13,159,846	9,208,157
Lease liabilities	2,758,472	2,980,535
Other financial liabilities	2,193,174	3,639,661

The fair values of cash and cash equivalents, trade and other receivables, other current assets, trade and other payables, other financial liabilities, lease liabilities and borrowings approximate to their carrying amounts largely due to being liquid assets or liabilities.

(b) Risk management policy

The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the consolidated entity's implementation of that system on a regular basis.

The Board and Senior Management identify the general areas of risk and assess the potential impact of any of these risks on the activities of the consolidated entity, with Management performing a regular review of:

- the major risks that may or do occur within the business;
- the degree of risk involved;
- the current approach of managing or mitigating the risk; and
- if appropriate, determine: any inadequacies of the current approach; and possible new approaches that more efficiently and effectively address the risk.

Financial risk management

Management report risks identified to the Board through regular reporting.

The consolidated entity seeks to ensure that its exposure to undue risk which may impact its financial performance, continued growth, and viability is minimised in a cost-effective manner.

The main risks the consolidated entity is exposed to through its operations are interest rate risk, credit risk, currency and liquidity risk.

Interest rate risk

The consolidated entity is exposed to interest rate risks via the cash and cash equivalents and borrowings that it holds. Interest rate risk is the risk that a financial instruments value will fluctuate because of changes in market interest rates. The objective of managing interest rate risk is to minimise the consolidated entity's exposure to fluctuations in interest rates that might impact its interest revenue, interest expense and cash flow.

3 Financial risk management (continued)

The consolidated entity has increased its borrowings during the year via a loan to acquire land and buildings, there have been no other material changes to the consolidated entity's exposure to interest rate risk. There has been no change to the manner in which it manages and measures its risk in the six months ended 31 December 2025.

The following table outlines the Consolidated entity's exposure to interest rate risk in relation to future cash flows and the effective weighted average interest rates on classes of financial assets and financial liabilities:

	Interest bearing	Non-interest bearing	Total carrying amount	Weighted average effective interest rate	Fixed / variable rate
	$	$	$		
31-Dec-25					
Financial assets					
Cash	31,135,046	4,630,155	35,765,201	3.95%	Variable
Trade and other receivables	-	1,554,880	1,554,880	-	
Prepayments	-	309,254	309,254	-	
Other current assets - security deposits	147,000	-	147,000	4.03%	Variable
Total financial assets	**31,282,046**	**6,494,289**	**37,776,335**		
Financial liabilities					
Trade and other payables	-	3,492,580	3,492,580	-	
Borrowings - bank loans	12,653,402	-	12,653,402	6.59%	Fixed
Borrowings - Insurance premium funding	84,885	-	84,885	4.49%	Fixed
Borrowings - other	421,559	-	421,559	6.05%	Fixed
Other financial liabilities - CSIRO	1,488,193	-	1,488,193	6.85%	Variable
Other financial liabilities - deferred consideration	25,545	-	25,545	6.85%	Variable
Contract liabilities	-	679,436	679,436	-	
Lease liabilities	2,758,472	-	2,758,472	4.74%	Fixed
Total financial liabilities	**17,432,056**	**4,172,016**	**21,604,072**		
30-Jun-25					
Financial assets					
Cash	4,239,537	4,686,910	8,926,447	3.31%	Variable
Trade and other receivables	-	351,612	351,612	-	
Prepayments	-	788,598	788,598	-	
Other current assets - security deposits	147,000	-	147,000	4.14%	Variable
Total financial assets	**4,386,537**	**5,827,120**	**10,213,657**		
Financial liabilities					
Trade and other payables	-	3,564,257	3,564,257	-	
Borrowings - bank loans	8,717,221	-	8,717,221	6.83%	Fixed
Borrowings - Insurance premium funding	339,566	-	339,566	4.49%	Fixed
Borrowings - other	151,370	-	151,370	8.03%	Fixed
Other financial liabilities - CSIRO	1,453,645	-	1,453,645	7.17%	Variable
Other financial liabilities - deferred and contingent consideration	25,319	-	25,319	7.17%	Variable
Contract liabilities	-	2,160,697	2,160,697	-	
Lease liabilities	2,980,535	-	2,980,535	4.80%	Fixed
Total financial liabilities	**13,667,656**	**5,724,954**	**19,392,610**		

No other financial assets or financial liabilities are expected to be exposed to interest rate risk.

3 Financial risk management (continued)

Profit and loss is sensitive to changes in interest income earned on cash and cash equivalents as a result in changes to deposit interest rates.

	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
1% change in interest rates		
Impact on loss after tax for the period	(138,500)	92,811
Impact on equity	138,500	(92,811)

The choice of 1% change in interest rates was determined having regard to the level of prevailing interest rates in Australia and the United States during 6 months ended 31 December 2025 and 12 months ended 30 June 2025.

Interest rate risk
The consolidated entity is exposed to interest rate risk via long-term and short-term borrowings.

The consolidated entity's bank loans outstanding for U.S. premises, totalling $8,469,826, are principal and interest payment loans and have a fixed interest rate through to May 2030.

The consolidated entity's bank loans outstanding for U.S. capital equipment, totalling $4,183,475, is an interest only loan with a fixed interest rate for the term of the loan.

Credit risk
The consolidated entity is exposed to credit risk via its cash and cash equivalents and trade and other receivables. Credit risk is the risk that a counter-party will default on its contractual obligations resulting in a financial loss to the consolidated entity. To reduce risk exposure for the consolidated entity's cash and cash equivalents, it places them with high credit quality financial institutions and performs background credit checks on counterparties where appropriate.

The consolidated entity holds the view that it does not have significant credit risk at this time in respect of its receivables.

Trade receivables consisted of a small number of transactions with multiple counterparties in the 6 months ended 31 December 2025. Ongoing credit evaluations are performed on the financial condition of each account receivable.

The maximum exposure to credit risk at balance date of recognised financial assets is the carrying amount of those assets net of any allowance for credit losses as disclosed in the Statement of Financial Position and Notes to the Financial Statements.

Currency risk
Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The consolidated entity from time to time may be exposed to foreign currency fluctuations due to overseas amounts receivable from customers, or payable to suppliers denominated in foreign currencies. The consolidated entity has bank accounts in, and holds cash balances in, the countries in which it operates therefore resulting in a natural hedge for part of its currency risk exposure.

Liquidity risk
The consolidated entity is exposed to liquidity risk via trade and other payables and borrowings.

Liquidity risk is the risk that the consolidated entity will encounter difficulty in raising funds to meet the commitments associated with its financial instruments. Responsibility for liquidity risk rests with the Board who manage liquidity risk by monitoring undiscounted cash flow forecasts and actual cash flows provided to them by the consolidated entity's Management to ensure that the consolidated entity continues to be able to meet its debts as and when they fall due.

Contracts are not entered into unless the Board believes that there are sufficient cash flows to fund the additional activity. The Board considers whether the consolidated entity needs to raise additional funding from the equity markets when reviewing its undiscounted cash flow forecasts.

3 Financial risk management (continued)

Remaining contractual maturities

The following tables detail the consolidated entity's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore, these totals may differ from their carrying amount in the statement of financial position.

	Less than 12 months	1-2 years	2-5 years	Over 5 years	Total contractual maturities
	$	$	$	$	$
31-Dec-25					
Non-derivatives					
Non-interest bearing					
Trade payables	2,177,939	-	-	-	2,177,939
Accrued expenses	1,151,696	-	-	-	1,151,696
Other payables	162,945	-	-	-	162,945
Interest bearing					
Borrowings - bank loans	4,944,145	718,584	4,682,465	9,559,312	19,904,506
Borrowings - Insurance premium funding	84,885	-	-	-	84,885
Borrowings - other	108,165	108,165	295,024	14,270	525,624
Other financial liabilities - CSIRO	90,000	90,000	360,000	1,800,000	2,340,000
Lease liabilities	473,416	297,869	716,339	2,109,222	3,596,846
Total non-derivatives	**9,193,191**	**1,214,618**	**6,053,828**	**13,482,804**	**29,944,441**
30-Jun-25					
Non-derivatives					
Non-interest bearing					
Trade payables	2,916,483	-	-	-	2,916,483
Accrued expenses	533,156	-	-	-	533,156
Other payables	114,618	-	-	-	114,618
Interest bearing					-
Borrowings - bank loans	734,272	734,272	5,093,068	9,696,796	16,258,408
Borrowings - Insurance premium funding	339,566	-	-	-	339,566
Borrowings - other	41,005	29,163	87,487	29,163	186,818
Other financial liabilities - CSIRO	90,000	90,000	330,000	1,875,000	2,385,000
Lease liabilities	475,018	421,091	731,472	2,275,689	3,903,270
Total non-derivatives	**5,244,118**	**1,274,526**	**6,242,027**	**13,876,648**	**26,637,319**

4 Fair value measurement

	6 months ended 31-Dec-25	**12 months ended 30-Jun-25**
	$	**$**
Fair value adjustment		
Fair value gain/(loss) on CSIRO IP liability	-	(65,443)
Fair value gain/(loss) on deferred and contingent acquisition consideration	-	210,828
	-	**145,385**

Fair value hierarchy

The following tables detail the consolidated entity's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

4 Fair value measurement (continued)

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date
Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
Level 3: Unobservable inputs for the asset or liability

	Level 1	Level 2	Level 3	Total
31-Dec-25	$	$	$	$
Assets				
Property, plant & equipment	-	-	-	-
Total assets	**-**	**-**	**-**	**-**
Liabilities				
Provision for deferred acquisition consideration	-	-	25,545	25,545
Total liabilities	**-**	**-**	**25,545**	**25,545**
30-Jun-25	$	$	$	$
Assets				
Property, plant & equipment	-	-	-	-
Total assets	**-**	**-**	**-**	**-**
Liabilities				
Provision for deferred acquisition consideration	-	-	25,319	25,319
Total liabilities	**-**	**-**	**25,319**	**25,319**

There were no transfers between levels during the current or prior financial year.

5 Segment information

Identification of reportable operating segments
The consolidated entity is organised into three operating segments. These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

The CODM reviews EBITDA (earnings before interest, tax, depreciation and amortisation). The accounting policies adopted for internal reporting to the CODM are consistent with those adopted in the financial statements.

The information reported to the CODM is on a monthly basis.

The consolidated entity operates in three geographical segments; located in the U.S, Australia and Netherlands. Segment details are therefore already deemed to be fully reflected in the body of the financial report.

The principal products and services of each of these operating segments are as follows:

- U.S.: High, medium and low pressure cold spray additive manufacturing machines for use by end customers. Strategic sales activities in aerospace and defence industries. Operational headquarters of the consolidated entity.
- Australia: High pressure, large scale cold spray additive manufacturing machines and manufactured products for customers in the aerospace, defence, oil and gas industries. R&D hub.
- Europe: Low and medium pressure cold spray additive manufacturing machines for use by end customers in providing various metal coating and repair services.

5 Segment information (continued)

Intersegment transactions

Intersegment transactions were made at market rates. Intersegment transactions are eliminated on consolidation.

Intersegment receivables, payables and loans

Intersegment loans are initially recognised at the consideration received. Intersegment loans receivable and loans payable that earn or incur non-market interest are not adjusted to fair value based on market interest rates. Intersegment loans are eliminated on consolidation.

6 months ended 31 December 2025	Australia $	U.S. $	Europe $	Consolidated $
Revenue				
External customer sales	479,404	2,764,404	764,438	4,008,246
Intersegment sales	*407,319*	-	*1,150,209*	*1,557,527*
Total sales revenue	886,722	2,764,404	1,914,647	5,565,773
Grant revenue	-	-	302,315	302,315
R&D tax incentive	-	-	-	-
Interest revenue	408,443	241,181	-	649,624
Other revenue	2,898	307,567	-	310,465
Intersegment management fees	*789,733*	*763,100*	-	*1,552,833*
Segment revenue	**2,087,796**	**4,076,252**	**2,216,962**	**8,381,010**
Intersegment eliminations				*(3,110,360)*
Total revenue				**5,270,650**
EBITDA	(7,503,663)	(6,208,872)	(1,129,194)	(14,841,729)
Depreciation and amortisation	(102,921)	(293,628)	(158,675)	(555,224)
Interest	24,420	(394,667)	(201,898)	(572,145)
Intersegment management fees	*(303,323)*	*(457,204)*	*(792,478)*	*(1,553,006)*
Intersegment eliminations				(329,195)
Loss before income tax expense	**(7,885,487)**	**(7,354,371)**	**(2,282,245)**	**(17,851,299)**
Income tax expense	-	-	-	-
Loss after income tax expense	**(7,885,487)**	**(7,354,371)**	**(2,282,245)**	**(17,851,299)**
Assets				
Segment assets	76,789,519	40,737,788	11,825,347	129,352,654
Intersegment eliminations				*(58,802,832)*
Total assets				**70,549,822**
Liabilities				
Segment liabilities	7,242,863	58,894,283	13,241,247	79,378,393
Intersegment eliminations				*(56,634,440)*
Total liabilities				**22,743,953**

5 Segment information (continued)

12 months ended 30 June 2025	Australia $	U.S. $	Europe $	Consolidated $
Revenue				
External customer sales	796,342	2,846,409	4,471,298	8,114,049
Intersegment sales	*495,762*	-	*2,336,407*	*2,832,169*
Total sales revenue	1,292,104	2,846,409	6,807,705	10,946,218
Grant revenue	56,600	-	95,821	152,421
R&D tax incentive	695,937	-	-	695,937
Interest revenue	417,263	5,810	6,834	429,907
Other revenue	7,030	28,595	(837)	34,788
Intersegment management fees	*2,494,790*	*1,034,711*	*363,184*	*3,892,685*
Segment revenue	**4,963,724**	**3,915,525**	**7,272,707**	**16,151,956**
Intersegment eliminations				*(6,724,854)*
Total revenue				**9,427,102**
EBITDA	(11,995,402)	(6,701,003)	(146,009)	(18,842,414)
Depreciation and amortisation	(83,210)	(28,255)	(230,950)	(342,415)
Interest	(185,361)	(50,781)	(59,937)	(296,079)
Intersegment management fees	*(896,672)*	*(1,509,109)*	*(1,403,928)*	(3,809,709)
Intersegment eliminations				*3,345,503*
Loss before income tax expense	**(13,160,645)**	**(8,289,148)**	**(1,840,824)**	**(19,945,114)**
Income tax expense	-	-	58,238	58,238
Loss after income tax expense	**(13,160,645)**	**(8,289,148)**	**(1,782,586)**	**(19,886,876)**
Assets				
Segment assets	33,703,172	20,447,136	8,898,989	63,049,297
Intersegment eliminations				*(27,949,259)*
Total assets				**35,100,038**
Liabilities				
Segment liabilities	7,313,348	31,641,297	8,345,113	47,299,758
Intersegment eliminations				*(27,014,767)*
Total liabilities				**20,284,991**

6 Revenue

	6 months ended 31-Dec-25 $	**12 months ended 30-Jun-25 $**
Sales revenue		
Revenue from contracts with customers	4,008,246	8,114,049
	4,008,246	**8,114,049**
Other revenue		
Research and development tax incentive	-	695,937
Other grants	302,315	152,421
Interest received	649,624	429,907
Other revenue	310,465	34,788
	1,262,404	**1,313,053**
	5,270,650	**9,427,102**

6 Revenue (continued)

Disaggregation of revenue

The disaggregation of revenue from contracts with customers is as follows:

	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Major product lines		
Machines	2,869,824	6,200,089
Projects	732,867	1,161,742
Consumables	405,555	752,218
	4,008,246	**8,114,049**
Geographical regions		
Australia	479,404	796,342
Europe	764,438	4,471,298
USA	2,764,404	2,846,409
	4,008,246	**8,114,049**

Timing of revenue recognition	Machines $	Projects $	Consumables $	Total $
6 months ended 31 December 2025				
Goods and services transferred at a point in time	1,931,916	732,867	405,555	3,070,338
Goods and services transferred over time	937,908	-	-	937,908
	2,869,824	**732,867**	**405,555**	**4,008,246**
12 months ended 30 June 2025				
Goods and services transferred at a point in time	4,397,402	1,161,742	752,218	6,311,362
Goods and services transferred over time	1,802,687	-	-	1,802,687
	6,200,089	**1,161,742**	**752,218**	**8,114,049**

Key revenue in excess of 10% of total revenue includes: the delivery of high-pressure and medium-pressure cold spray systems to Triton System Inc. in the U.S. for $1,692,025, and partial recognition of a high-pressure system sale to University of North Texas for $523,781.

7 Expenses

	Note	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Employee benefits expenses			
Share-based payments		3,667,145	6,026,275
Superannuation		730,561	987,865
Salaries, wages and other employee benefits		6,369,531	8,684,841
		10,767,237	**15,698,981**
Depreciation and amortisation expenses			
Depreciation on property, plant and equipment	**17**	464,943	211,625
Depreciation on right of use assets	**18**	90,281	130,790
		555,224	**342,415**
Finance costs			
Other interest		20,968	17,528
Lease liabilities		82,010	100,297
Interest on loans (U.S. premises & capital equipment)		389,393	50,781
Notional interest on other liabilities		79,774	127,473
		572,145	**296,079**

8 Remuneration expense on Tri-D transaction and Dycomet acquisition

	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Share-based payments (EU - Dycomet)	-	18,181
Taxes due (US - Tri-D)	-	-
	-	**18,181**

Tri-D Dynamic Inc. Transaction

On 09 July 2021, the Company entered into an Asset Purchase Agreement. In the Agreement, Tri-D Dynamics Inc. (Tri D) agreed to sell substantially all the assets and liabilities of the company. This transaction did not meet the definition of a business and therefore was not accounted for in accordance with AASB 3 Business Combinations. The expenses above reflect accelerated share-based payments to one of the Tri-D Dynamics founders.

As such, the Company has accounted for these cash and share-based payments in accordance with AASB 119 Employee benefits and AASB 2 Share-Based payment.

Dycomet Europe B.V. acquisition (now trading as Titomic Europe B.V.)

Pursuant to the acquisition of Dycomet Europe B.V., the consideration included cash and equity. All other considerations have been delivered as at 31 December 2025, apart from 2nd earn-out component. Further details are disclosed in note 23.

9 Share based payment expenses

	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Share-based payments - directors	500,313	4,997,714
Share-based payments - directors - forfeiture	-	(326,759)
Share-based payments - employees & consultants	3,166,832	1,355,320
	3,667,145	**6,026,275**

10 Income tax expense

	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Income tax expense		
Income tax expense	-	(58,238)
Aggregate income tax expense	-	(58,238)
Reconciliation of income tax expense to prima facie tax payable		
Loss before income tax expense	(17,851,299)	(19,945,114)
Tax at the statutory rate 25% (30 June 2025: 25%)	(4,462,825)	(4,986,279)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Non-assessable research and development tax incentive income	-	(173,824)
Non-allowable expenses	1,118,283	1,890,438
Tax losses for which no deferred tax asset is recognised	960,954	1,456,736
Timing differences for which no deferred tax asset is recognised	(507,160)	191,910
Impact of different subsidiary tax rates	513,409	360,950
Tax losses of foreign controlled entities not recognised	2,377,339	1,201,831
Income tax expense	-	(58,238)

The income tax expense in prior period relates to Titomic Europe B.V. (domiciled in The Netherlands).

Unrecognised potential tax benefits		
Unused tax losses for which no deferred tax asset has been recognised - Australia	17,674,995	16,714,041
Unused tax losses for which no deferred tax asset has been recognised - USA	3,559,589	1,786,253
Unused tax losses for which no deferred tax asset has been recognised - Netherlands	611,774	7,772

The potential tax benefits can only be utilised by the consolidated entity in the future if it generates sufficient tax profits and in relation to tax losses, the continuity of ownership test is passed or failing that, the same business test is passed.

11 Earnings / (loss) per share

	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Earnings / (loss) per share from continuing operations		
Net loss after income tax	(17,851,299)	(19,886,876)
Net loss after income tax attributable to the owners of Titomic Limited	(17,851,299)	(19,886,876)
	Number	**Number**
Weighted average number of ordinary shares used in calculating basic earnings per share	1,505,589,601	1,213,259,615
Weighted average number of ordinary shares used in calculating diluted earnings per share	1,505,589,601	1,213,259,615
	$	**$**
Basic earnings / (loss) per share	(0.0119)	(0.0164)
Diluted earning / (loss) per share	(0.0119)	(0.0164)

11 Earnings / (loss) per share (continued)

During a loss period, the effect of the potential exercise of stock options and performance rights is not considered in the diluted loss per share calculation since the effect would be anti-dilutive.

5,892,858 (30 June 2025: 65,892,858) rights and 203,741,786 (30 June 2025: 201,313,286) options have been excluded from the above calculations as their inclusion would be anti-dilutive.

12 Cash and cash equivalents

	31-Dec-25	30-Jun-25
	$	$
Cash at bank	35,765,201	8,926,447

13 Trade and other receivables

	31-Dec-25	30-Jun-25
	$	$
Trade receivables	1,092,057	305,358
Less: provision for estimated credit losses	(17,724)	(11,927)
Interest receivable	418,685	-
Other receivables	61,862	58,181
	1,554,880	**351,612**

Allowance for expected credit losses
The consolidated entity has recognised a loss of $5,796 in profit or loss in respect of the expected credit losses for the 6 months ended 31 December 2025.

The ageing of the receivables and the provision for expected credit losses provided for above are as follows:

	Expected credit loss rate		Carrying amount		Allowance for expected credit losses	
	31-Dec-25	30-Jun-25	31-Dec-25	30-Jun-25	31-Dec-25	30-Jun-25
Consolidated	%	%	$	$	$	$
Not overdue	-	-	798,501	121,409	-	-
0 to 3 months overdue	-	-	266,734	164,906	-	-
3 to 6 months overdue	-	-	9,099	-	-	-
Over 6 months overdue	100	63	17,723	19,043	(17,724)	(11,927)
			1,092,057	**305,358**	**(17,724)**	**(11,927)**

Movements in the provision for expected credit losses are as follows:

	31-Dec-25	30-Jun-25
	$	$
Opening balance	11,927	53,181
Additional provisions recognised	5,797	11,927
Provision written-off	-	(53,181)
Closing balance	**17,724**	**11,927**

14 Inventories

	31-Dec-25	30-Jun-25
	$	$
Raw materials at cost	1,188,089	1,714,321
Less: Provision for obsolescence	(395,885)	(349,904)
Work in progress at cost	1,974,222	2,547,862
Less: Provision for obsolescence	(489,359)	(642,730)
Finished goods at cost	1,160,818	903,967
	3,437,885	**4,173,516**

15 Contract assets

	31-Dec-25	30-Jun-25
	$	$
Contract assets	-	581,585

Contract assets

Contract assets are recognised when the consolidated entity has transferred goods and services but has not yet established an unconditional right to receive consideration. The balances represent the consolidated entity's right to consideration for goods and services provided in relation to the sale of Titomic Kinetic Fusion systems.

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial years are set out below:

	Australia	U.S.	Europe	Consolidated
Balance at 1-Jul-24	-	-	-	-
Additions	-	581,585	-	581,585
Balance at 30-Jun-25	-	581,585	-	581,585
Additions	-	-	-	-
Transfer to trade receivables	-	(581,585)	-	(581,585)
Balance at 31-Dec-25	-	-	-	-

16 Other current assets

	31-Dec-25	30-Jun-25
	$	$
Prepayments	309,254	788,598
Security deposits	147,000	147,000
	456,254	**935,598**

17 Property, plant and equipment

	31-Dec-25	30-Jun-25
	$	$
Building fitouts	2,259,679	624,487
Less: accumulated depreciation	(540,906)	(341,420)
Less: provision for impairment	(22,540)	(22,540)
	1,696,233	260,527
Factory equipment & machinery	11,038,899	8,208,815
Less: accumulated depreciation	(6,081,590)	(6,025,376)
Less: provision for impairment	(720,694)	(720,694)
	4,236,615	1,462,745
Computer equipment & software	841,247	688,373
Less: accumulated depreciation	(411,490)	(359,858)
Less: provision for impairment	(30,768)	(30,769)
	398,989	297,746
Land & building	10,792,731	11,028,359
Less: accumulated depreciation	(148,850)	(21,728)
	10,643,881	11,006,631
Capital work in progress	9,868,218	4,466,339
	26,843,936	**17,493,988**

U.S. premises purchase
On 29 May 2025, the consolidated entity executed an agreement to acquire premises located at 15091 US Highway 20, Madison, Alabama 35756 in the United States. The purchase price was USD $7,200,000 (AUD $10,757,508) plus acquisition costs.

Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial years are set out below:

	Building fitouts	Factory equipment & machinery	Computer equipment & software	Land & building	Capital work in progress	Total
	$	$	$	$	$	$
Balance at 1-Jul-24	97,518	406,789	32,231	-	-	536,538
Additions	77,404	1,269,257	278,609	11,028,359	3,554,193	16,207,822
Transfer	103,259	(133,227)	29,968	-	133,227	133,227
Transfer from inventory	-	-	-	-	778,919	778,919
Asset written off	-	-	(893)	-	-	(893)
Depreciation expense	(33,360)	(110,831)	(45,479)	(21,956)	-	(211,626)
Effect of foreign exchange	15,706	30,757	3,310	228	-	50,001
Balance at 30-Jun-25	260,527	1,462,745	297,746	11,006,631	4,466,339	17,493,988
Additions	1,201,963	3,008,971	169,090	-	5,831,843	10,211,867
Transfer	309,893	(197,595)	(9,836)	-	(102,462)	-
Transfer from inventory	-	192,203	-	-	(201,352)	(9,149)
Depreciation expense	(73,342)	(208,037)	(53,335)	(130,229)	-	(464,943)
Intercompany eliminations	-	-	-	-	(44,519)	(44,519)
Effect of foreign exchange	(2,808)	(21,672)	(4,676)	(232,521)	(81,631)	(343,308)
Balance at 31-Dec-25	1,696,233	4,236,615	398,989	10,643,881	9,868,218	26,843,936

18 Right-of-use assets

	31-Dec-25	30-Jun-25
	$	$
Buildings: right-of-use	3,642,023	3,698,389
Less: accumulated depreciation	(450,965)	(364,526)
Less: provision for impairment	(730,289)	(730,289)
	2,460,769	**2,603,574**

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial years are set out below:

	Australian factory	Australian head office	Netherlands manufacturing facility (old)	Netherlands manufacturing facility	Total
	$	$	$	$	$
Balance at 1-Jul-24	-	-	19,313	-	19,313
Additions	-	-	-	2,724,670	2,724,670
End of lease - Right of use asset	-	(438,930)	(132,225)	-	(571,155)
End of lease - accumulated depreciation	-	195,080	132,225	-	327,305
End of lease - impairment provision	-	243,850	-	-	243,850
Impairment of assets		-	-	-	-
Depreciation expense	-	-	(19,313)	(111,477)	(130,790)
Effect of foreign exchange	-	-	-	(9,619)	(9,619)
Balance at 30-Jun-25	-	-	-	2,603,574	2,603,574
Depreciation expense	-	-	-	(90,281)	(90,281)
Effect of foreign exchange	-	-	-	(52,524)	(52,523)
Balance at 31-Dec-25	-	-	-	2,460,769	2,460,769

The details in relation to material lease arrangements are explained in note 22.

19 Trade and other payables

	31-Dec-25	30-Jun-25
	$	$
Trade payables	2,177,939	2,916,483
Accrued expenses	1,151,696	533,156
Other payables	162,945	114,618
	3,492,580	**3,564,257**

20 Provisions

	31-Dec-25	30-Jun-25
	$	$
Current		
Employee benefits	760,716	472,244
Warranties	75,957	85,765
Taxes payable on Tri-D transaction	168,086	171,756
	1,004,759	**729,765**
Non-current		
Employee benefits	61,197	88,748
Lease make good	73,925	73,868
	135,122	**162,616**

21 Borrowings

	31-Dec-25	30-Jun-25
	$	$
Current		
Insurance premium funding	84,885	339,566
Interest-bearing loans (U.S. premises)	132,102	131,654
Interest-bearing loans (U.S. capital equipment)	4,183,475	-
Other	84,351	30,847
	4,484,813	**502,067**
Non-current		
Interest-bearing loans (U.S. premises)	8,337,824	8,585,567
Other	337,209	120,523
	8,675,033	**8,706,090**

During the current and prior years, the consolidated entity utilised an insurance premium funding facility which is repaid in monthly instalments across the duration of the insurance premium.

Interest-bearing loans (U.S. premises)
On 29 May 2025, the consolidated entity entered into two interest-bearing loans with First National Bank of Pulaski. The loans were in two tranches of $5,740,458 (USD $3,760,000) and $3,053,435 (USD $2,000,000). Titomic USA, Inc. has granted a first mortgage to First National Bank of Pulaski as security for both loans over the land and buildings located at 15091 US Highway 20, Madison, Alabama 35756.

The USD $3,760,000 tranche incurs interest at a rate of 7% p.a. (WSJ Prime Rate minus 0.5% p.a. fixed for five years) with principal and interest repayments over 25 years.

The USD $2,000,000 tranche incurs interest at a rate of 6.5% p.a. (fixed for five years) and is repayable after five years with principal and interest repayments calculated using a 25 year schedule. This tranche is also secured by USD $1,000,000 collateral provided by Innovate Alabama to the First National Bank of Pulaski.

The bank loans are subjects to certain covenants with the material covenants being as follows:
- establishment of an escrow account equal to 18 months worth of principal and interest payments. These funds, totalling $1,094,793 (US$732,745) plus interests will be released from escrow when a debt service coverage of 1.25 times is reached.
- borrower is expected to reach a debt service coverage of 1.25 times by 30 June 2027.
- borrower's capital level will remain at the same level on the day of the loan's origination.

The financial covenants are assessed at the end of each fiscal year. The loans could be repayable immediately if the covenants are breached. The consolidated entity is not aware of any facts or circumstances that indicate that it may have difficulty complying with the covenants within 12 months after the reporting period.

Interest-bearing loans (U.S. capital equipment)
On 3 September 2025, the consolidated entity entered into an interest-bearing revolving line of credit (RLOC) loan agreement with First National Bank of Pulaski. The loan has a maximum credit capacity of $11,205,737 (US$7,500,000) and is secured by the consolidated entity's US$7,500,000 cash deposit. Any drawn amount from this RLOC will incur an interest at a rate of 6.12% which is paid monthly.

As at balance date, $4,183,475 (US$2,800,000) has been drawn from this line of credit.

Other borrowings
In June 2025, the consolidated entity entered into a vehicle loan with First National Bank of Pulaski for $139,528 (USD $91,391), incurring a fixed interest rate of 7.65% p.a. with repayments over 6 years.

During the reporting period, the consolidated entity entered into two borrowing arrangements for metallurgy equipment for $137,524 and$172,658, incurring fixed interest rates of 10.12% p.a. and 10.82% p.a. respectively, with repayments over 5 years.

As at 31 December 2025, the consolidated entity had unused bank overdraft facility of $175,316 (EUR €100,000) with Rabobank in the Netherlands.

22 Lease liabilities

	31-Dec-25	30-Jun-25
	$	$
Current		
Lease liabilities - Australian factory	224,129	213,625
Lease liabilities - Netherlands manufacturing facility	132,691	132,529
	356,820	**346,154**
Non-current		
Lease liabilities - Australian factory	58,774	173,515
Lease liabilities - Netherlands manufacturing facility	2,342,878	2,460,866
	2,401,652	**2,634,381**

Information in relation to the lease liabilities is below:

Maturity analysis - contractual undiscounted cash flows		
Less than one year	473,416	475,018
One to two years	297,869	421,091
Two to five years	716,339	731,472
More than five years	2,109,222	2,275,689
Total undiscounted lease liabilities	3,596,846	3,903,270

The consolidated entity has the below material leases for premises as follows:

Australian factory
The lease for the existing location of the factory was extended effective from 1 April 2022 for a further five years with an expiry date of 31 March 2027. There is a five year option to extend at the end of the current term.

Netherlands manufacturing facility
The lease for a new location for Titomic Europe's manufacturing facility located in Heerenveen, the Netherlands was executed effective from 1 November 2024 for an initial term of ten years with an expiry date of 31 October 2034. There is a five year option to extend at the end of the initial term.

Equipment
The consolidated entity also entered leasing arrangements for its equipment. For low value office equipment, these leases are either short-term or low-value, so have been expensed as incurred and not capitalised as right-of-use assets. For high value factory equipment, these leases are accounted as per AASB 16.

23 Other financial liabilities

	31-Dec-25	30-Jun-25
	$	$
Current		
CSIRO IP liability	90,000	90,000
Variable deferred consideration for Dycomet (now Titomic Europe B.V.) acquisition	25,545	-
Contract liabilities	679,436	2,160,697
	794,981	**2,250,697**
Non-current		
CSIRO IP liability	1,398,193	1,363,645
Variable deferred consideration for Dycomet (now Titomic Europe B.V.) acquisition	-	25,319
	1,398,193	**1,388,964**

23 Other financial liabilities (continued)

CSIRO IP liability

The consolidated entity has three core pieces of Intellectual Property (IP) around its Titomic Kinetic Fusion (TKF) Cold Spray robotic technology manufacturing process. TKF is the process of spraying metal powders at supersonic speed (up to two times the speed of sound) onto a scaffold surface, resulting in the powder particles plastically deforming at the edges and, on impact, bonding at a particle level with the surrounding particles.

The consolidated entity has exclusively licensed the IP for three royalty-bearing licences owned by the Commonwealth Scientific and Industrial Research Organisation (CSIRO). The licences are in respect of:

(1) *Patent Application No PCT/AU2013/000318* "A Process For Producing A Titanium Load-bearing Structure", and any applicable Know-How and relevant subject matter;

(2) *Patent Application No PCT/AU2009/000276* "Manufacture of Pipes" using Titanium and Titanium Alloys; and any applicable Know-How and relevant subject matter; and

(3) *Patent Application No PCT/AU2013/001382* "Method of forming seamless pipe of titanium and/or titanium alloys", and any applicable Know How and relevant subject matter.

The term of these licences is to the expiration, lapsing or cessation of all licenced patents, a maximum of 20 years or the life of the underlying patent.

Under the agreement, the consolidated entity must pay CSIRO 1.5% of attributable gross sales revenue attributed to products produced utilising the licensed patented technologies within the licensed field and 20% of non-sales revenue attributable to products produced using the licensed patented process within the licensed field.

Minimum royalty payments are structured as follows:

Period	$
FY2025-FY2029	90,000
FY2030-FY2032	150,000
FY2033-FY2035	225,000
FY2036-FY2038	300,000

The above performance criteria is discounted using an indicative discount rate of 6.85% p.a. and has been spread over the period to determine the value of the intangible asset acquired.

Reconciliation of the balance of the CSIRO IP liability at the beginning and end of the current and previous financial years are set out below:

	31-Dec-25	**30-Jun-25**
	$	**$**
CSIRO IP liability at the start of the financial year	1,453,645	1,366,436
Payments made during the year	(45,000)	(90,000)
Interest on unwinding of discount	79,548	111,766
Fair value (gain)/loss on contract amendment during the year	-	65,443
Closing balance	**1,488,193**	**1,453,645**

Deferred and contingent consideration for Dycomet (now Titomic Europe B.V.) acquisition

On 30 November 2021, Titomic Limited acquired 100% of the ordinary shares of Dycomet Europe B.V. (now Titomic Europe B.V.). Pursuant to the agreement the seller was owed a deferred payment of EUR €150,000 eighteen months after the acquisition date (this was paid during the 2024 financial year) and a further payment of EUR €150,000 three years after the acquisition date (this was paid in November 2024).

23 Other financial liabilities (continued)

In addition, there are two earnout components calculated as a percentage of revenue payable three years and five years after the acquisition date. The first earnout is contingent upon a key employee being in continued employment on 30 November 2024 (this was paid in November 2024). The second of these payments is not subject to the employment conditions.

Reconciliation of the balance of deferred and contingent consideration for Dycomet at the beginning and end of the current and previous financial years are set out below:

	31-Dec-25	30-Jun-25
	$	$
Deferred and contingent consideration at the start of the financial year	25,319	492,413
Payment for deferred consideration	-	(271,973)
Interest on unwinding of discount	226	15,707
Fair value (gain)/loss on remeasurement on deferred and contingent consideration	-	(210,828)
Closing balance	**25,545**	**25,319**

Contract liabilities

Contract liabilities represent the consolidated entity's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration or when the consolidated entity recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the consolidated entity has transferred the goods or services to the customer.

Reconciliation of the balance of contract liabilities at the beginning and end of the current and previous financial years are set out below:

	31-Dec-25	30-Jun-25
	$	$
Contract liabilities at the start of the financial year	2,160,697	1,419,104
Payments received in advance	1,841,844	3,439,945
Transfer to revenue - performance obligations satisfied	(3,232,262)	(2,698,352)
Transfer to other liabilities	(50,000)	-
Effect of foreign exchange	(40,843)	-
Closing balance	**679,436**	**2,160,697**

Unsatisfied performance obligations

The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied at the end of the reporting period was $2,041,384 as at 31 December 2025 (30 June 2025: $2,604,234) and is expected to be recognised as revenue in future periods as follows:

	31-Dec-25	30-Jun-25
	$	$
Within 6 months	1,594,329	3,682,152
6 to 12 months	447,055	427,624
	2,041,384	4,109,776

24 Issued capital

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

	31-Dec-25	30-Jun-25	31-Dec-25	30-Jun-25
	Shares	Shares	$	$
Ordinary shares - fully paid	1,599,400,057	1,325,758,397	72,655,460	23,130,710

24 Issued capital (continued)

Movements in ordinary share capital - for the 12 months ended 30 June 2025

Details	Date	Shares	Issue price / value	$
Opening balance	1-Jul-24	1,010,635,855		75,211,575
Issue of share capital to employees	9-Jul-24	342,265	0.083	28,408
Issue of share capital to employees	7-Aug-24	12,260,000	0.018	220,680
Issue of share capital to consultants	8-Aug-24	2,000,000	0.050	100,000
Issue of share capital to employees	3-Sep-24	461,935	0.255	117,793
Issue of share capital to employees	3-Sep-24	6,178,672	0.018	111,216
Issue of share capital	22-Oct-24	143,211,735	0.120	17,185,408
Issue of share capital	4-Dec-24	106,788,265	0.120	12,814,592
Issue of share capital for Dycomet consideration	11-Dec-24	500,000	0.204	101,889
Issue of share capital to directors	13-Dec-24	40,000,000	0.015	592,000
Issue of share capital to employees	20-Dec-24	99,763	0.255	25,440
Issue of share capital to employees	20-Dec-24	3,279,907	0.018	59,038
Less: technical adjustment to share capital	28-Feb-25			(81,503,186)
Less: other adjustments				(5,686)
Less: transaction costs arising on issue of shares				(1,928,457)
Closing balance	30-Jun-25	1,325,758,397		23,130,710

Movements in ordinary share capital - for the 6 months ended 31 December 2025

Details	Date	Shares	Issue price / value	$
Opening balance	1-Jul-25	1,325,758,397		23,130,710
Issue of share capital	31-Jul-25	200,000,000	0.250	50,000,000
Issue of share capital to consultant	7-Oct-25	2,000,000	0.070	140,000
Issue of share capital to employees	10-Oct-25	9,161,019	0.018	164,898
Issue of share capital to employees	10-Oct-25	276,123	0.315	86,979
Issue of share capital to directors	4-Dec-25	17,500,000	0.014	246,750
Issue of share capital to directors	4-Dec-25	17,500,000	0.012	204,750
Issue of share capital to directors	19-Dec-25	1,400,000	0.250	350,000
Issue of share capital to directors	19-Dec-25	804,518	0.265	213,197
Issue of share capital to directors	19-Dec-25	10,000,000	0.014	141,000
Issue of share capital to directors	19-Dec-25	10,000,000	0.012	117,000
Issue of share capital to directors	19-Dec-25	5,000,000	0.195	975,000
Less: transaction costs arising on issue of shares				(3,114,824)
Closing balance	31-Dec-25	1,599,400,057		72,655,460

24 Issued capital (continued)

Technical adjustment to share capital
In February 2025, the consolidated entity's Board of Directors resolved to reduce the share capital of the Company by $81,503,186 in accordance with Section 258F of the Corporations Act 2001 (Cth) (Corporation Act).

The capital adjustment had the effect of reducing the share capital account and reducing 'Accumulated Losses' in the Company's financial statements. This is a technical adjustment which does not impact the net assets, financial results, cash flow or funding of the Company or its consolidated group.

The adjustment was made to ensure the Company's European subsidiary, Titomic Europe, was eligible for material grant funding that relies on the Company meeting pre-determined financial metrics.

Under Section 258F(1) of the Corporation Act, a company may reduce its share capital by cancelling any paid up share capital that is not represented by available assets. As at 31 December 2024 the Company had accumulated losses of AU$91,169,793 and its net assets (at the parent entity level) were less than its share capital.

The number of securities on issue in the Company was not affected and no amount was unpaid on any of its securities pursuant to the capital reduction; and there are no fractional entitlements arisen from the capital reduction.

Capital risk management
The consolidated entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

Management assesses the Company's capital requirements in order to maintain an efficient overall financing structure and considers adjustments to it in light of changes to economic conditions and the risk characteristics of its economic activities. In order to maintain or adjust the capital structure, the Company may issue new shares.

The consolidated entity is subject to certain financing arrangements covenants and meeting these is given priority in all capital risk management decisions. There have been no events of default on the financing arrangements during the financial year.

25 Reserves

	31-Dec-25 $	30-Jun-25 $
Foreign currency translation reserve	(855,170)	(654,971)
Share based payment reserves (a)	16,839,363	15,321,793
	15,984,193	**14,666,822**

(a) share based payment reserves comprises:

	31-Dec-25 $	30-Jun-25 $
Rights reserve	1,107,530	2,258,004
Options reserve	7,388,683	4,844,626
Shares reserve	84,787	-
Forfeited shares, rights and options reserve	8,258,363	8,219,163
	16,839,363	15,321,793

Foreign currency translation reserve
The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations.

25 Reserves (continued)

Rights reserve

The rights reserve reflects directors and employee rights.

Directors rights - approved at the 2023 AGM

At the Annual General Meeting held on 23 November 2023, shareholders approved resolutions for all performance rights currently held by directors as at the date of the meeting to be forfeited by the relevant directors, and adjusted performance rights to be issued at the same time. The below table reflects rights that were issued:

Grant date	Number of rights	Hurdle price	Exercise price	Expiry date	Fair value ($)
4-Dec-23	40,000,000	$0.030	$0.000	4-Dec-26	592,000
4-Dec-23	40,000,000	$0.050	$0.000	4-Dec-27	564,000
4-Dec-23	40,000,000	$0.070	$0.000	4-Dec-27	468,000
	120,000,000				1,624,000

The performance hurdle for the rights issued was based on the company's 15-day VWAP share price and set in three tranches at $0.030, $0.050 and $0.070.

The fair value of the rights has been calculated using the Monte Carlo simulation model using the following key assumptions and inputs, explained below:

Grant date	Number of rights	Spot price	Risk-free rate (%)	Expiry date	Volatility rate (%)	Fair value ($)
4-Dec-23	40,000,000	$0.020	4.14%	4-Dec-26	100.00%	592,000
4-Dec-23	40,000,000	$0.020	4.16%	4-Dec-27	100.00%	564,000
4-Dec-23	40,000,000	$0.020	4.16%	4-Dec-27	100.00%	468,000
	120,000,000					1,624,000

Risk-Free rate: Observed by reference to Commonwealth Government securities for the applicable periods.

The 40,000,000 rights with a hurdle price of $0.030 have been converted to ordinary shares in December 2024.

The 27,500,000 rights with a hurdle price of $0.050 have been converted to ordinary shares in December 2025 and 12,500,000 rights with the same hurdle price have been forfeited in July 2025.

The 27,500,000 rights with a hurdle price of $0.070 have been converted to ordinary shares in December 2025 and 12,500,000 rights with the same hurdle price have been forfeited in July 2025.

Managing director rights - November 2024

On 18 November 2024, Jim Simpson has entered agreement contract with the consolidated entity to become its Managing Director. As per the contract, Mr Simpson will receive 5,000,000 rights at no cost which shall vest on 18 November 2025, subject to shareholder approval at the 2025 AGM.

As at 30 June 2025, the consolidated entity has accrued for Mr Simpson's rights expense at a fair value of $0.30 per right, totalling $1,500,000.

At the Annual General Meeting held on 25 November 2025, shareholders approved Mr Simpson's rights remuneration package and 5,000,000 rights have been converted to ordinary shares in December 2025.

25 Reserves (continued)

As at 31 December 2025, Mr Simpson's rights expense was revalued at a fair value of $0.195 per right, totalling $975,000, which related share based payments expense and reserves allocation were adjusted accordingly.

Employees rights

Senior management employees incentive plan
On 30 May 2025, the Board of Directors approved the issue of 5,892,858 rights to senior management employees, following the recommendation from the Remuneration and Nomination Committee Meeting held on 8 May 2025. The issued rights are related to a sign on bonus as part of employment agreements with US based senior management, as per below:

Grant date	Number of rights	Hurdle price	Exercise price	Expiry date	Fair value ($)
1-Jan-25	4,642,858	$0.000	$0.000	31-Dec-25	882,143
21-Apr-25	1,250,000	$0.000	$0.000	21-Apr-26	281,250
	5,892,858				1,163,393

The fair value of the rights has been calculated on the basis of the Monte Carlo model using the following key assumptions:

Grant date	Number of options	Spot price	Risk-free rate (%)	Expiry date	Volatility rate (%)	Fair value ($)
1-Jan-25	4,642,858	$0.190	3.83%	31-Dec-25	110.00%	882,143
21-Apr-25	1,250,000	$0.225	3.29%	21-Apr-26	110.00%	281,250
	5,892,858					1,163,393

Risk-Free rate: Observed by reference to Commonwealth Government securities for the applicable periods.

Senior management employees incentive plan - EU
In October 2025, in recognition of the long servitude and a successful expansion of European subsidiary, the Board approved the issue of 828,369 rights to a senior management employee. The rights shall be vested in three tranches on 9 October of calendar year 2025, 2026 and 2027 contingent on employment.

The first 276,123 rights were vested and 276,123 shares were issued in October 2025.

The fair value of the shares has been determined using share price on the board approval date at $0.315 per share.

Employee incentive plan
In September 2023, the directors established an employee LTI plan and for certain retention incentives. The plan is designed to align the interests of eligible employees more closely with the interests of the consolidated entity by providing an opportunity for eligible employees to receive an equity interest in the consolidated entity. Certain employees were allotted share rights in three tranches, which would vest over time.

The first tranche vested immediately and the shares were issued in April 2024. The second tranche vested in September 2024 and the shares were issued in September 2024 (for Australian employees) and December 2024 (for European employees). The third & final tranche vested in September 2025 and the shares are were issued in October 2025.

The share rights were valued at the market closing price on 8 Sept 2023 of $0.018. There was no adjustment for the impact of discounting as it is deemed to be immaterial.

25 Reserves (continued)

Options reserve
The options reserve reflects directors and employee rights.

The weighted average remaining contractual life of options outstanding at 31 December 2025 was 3.41 years (30 June 2025: 3.76 years)

Director options - AGM 2023
At the Annual General Meeting on 23 November 2023, shareholders approved resolutions for all options currently held by directors as at the date of the meeting to be forfeited by the relevant directors, and adjusted options to be issued at the same time. The below table reflects options that were issued:

Grant date	Number of options	Hurdle price	Exercise price	Expiry date	Fair value ($)
4-Dec-23	52,500,000	$0.030	$0.000	4-Dec-26	777,000
4-Dec-23	62,500,000	$0.050	$0.000	4-Dec-27	881,250
4-Dec-23	27,500,000	$0.070	$0.000	4-Dec-27	321,750
	142,500,000				1,980,000

The performance hurdle for the options issued on 4-Dec-23 was based on the company's 15-day VWAP share price and set in three tranches at $0.030, $0.050 and $0.070.

The fair value of the options has been calculated on the basis of the Black Scholes model using the following key assumptions:

Grant date	Number of options	Spot price	Risk-free rate (%)	Expiry date	Volatility rate (%)	Fair value ($)
4-Dec-23	52,500,000	$0.020	4.14%	4-Dec-26	100.00%	777,000
4-Dec-23	62,500,000	$0.020	4.16%	4-Dec-27	100.00%	881,250
4-Dec-23	27,500,000	$0.020	4.16%	4-Dec-27	100.00%	321,750
	142,500,000					1,980,000

Risk-Free rate: Observed by reference to Commonwealth Government securities for the applicable periods.

Director options - AGM 2025
At the Annual General Meeting on 25 November 2025, shareholders approved the issue of options to John Frewen as below:

Grant date	Number of options	Hurdle price	Exercise price	Expiry date	Fair value ($)
25-Nov-25	1,250,000	$0.440	$0.000	19-Dec-33	236,086
25-Nov-25	1,750,000	$0.770	$0.000	19-Dec-34	325,417
25-Nov-25	2,000,000	$1.000	$0.000	19-Dec-35	372,073
	5,000,000				933,576

The performance hurdle for the options issued on 19-Dec-25 was based on the company's 15-day VWAP share price and set in three tranches at $0.440, $0.770 and $1.000.

25 Reserves (continued)

The fair value of the options has been calculated on the basis of the Black Scholes model using the following key assumptions:

Grant date	Number of options	Spot price	Risk-free rate (%)	Expiry date	Volatility rate (%)	Fair value ($)
25-Nov-25	1,250,000	$0.195	3.90%	19-Dec-33	102.47%	236,086
25-Nov-25	1,750,000	$0.195	3.90%	19-Dec-34	102.47%	325,417
25-Nov-25	2,000,000	$0.195	3.90%	19-Dec-35	102.47%	372,073
	5,000,000					933,576

Risk-Free rate: Observed by reference to Commonwealth Government securities for the applicable periods.

Director options - Managing Director - November 2024
On 18 November 2024, Jim Simpson executed an executive employment agreement with the consolidated entity to become Managing Director. As per the agreement, Mr Simpson is entitled to receive options in three tranches of 5,000,000 options, 10,000,000 options and 10,000,000 options which shall vest on 18 November of calendar year 2025, 2026 and 2027 respectively. The grant of these options was subject to shareholder approval at the 2025 AGM.

As at 30 June 2025, the consolidated entity has accrued for Mr Simpson's options expense at a fair value of $0.30 per option, totalling $7,500,000.

At the Annual General Meeting held on 25 November 2025, shareholders approved Mr Simpson's options remuneration package.

As at 31 December 2025, Mr Simpson's options expense was revalued as per below, which related share based payments expense and reserves allocation were adjusted accordingly:

Grant date	Number of options	Hurdle price	Exercise price	Expiry date	Fair value ($)
25-Nov-25	5,000,000	$0.150	$0.000	18-Nov-32	975,000
25-Nov-25	10,000,000	$0.180	$0.000	18-Nov-33	1,950,000
25-Nov-25	10,000,000	$0.300	$0.000	18-Nov-34	1,633,266
	25,000,000				4,558,266

The performance hurdles for the three tranches are based on the company’s 15-day VWAP share price at $0.150, $0.180 and $0.300 respectively.

The fair value of the options has been calculated on the basis of the Black Scholes model using the following key assumptions:

Grant date	Number of options	Spot price	Risk-free rate (%)	Expiry date	Volatility rate (%)	Fair value ($)
25-Nov-25	5,000,000	$0.195	n/a	18-Nov-32	n/a	975,000
25-Nov-25	10,000,000	$0.195	n/a	18-Nov-33	n/a	1,950,000
25-Nov-25	10,000,000	$0.195	3.90%	18-Nov-34	102.47%	1,633,266
	25,000,000					4,558,266

For the first two tranches of options with hurdle prices of $0.150 and $0.180, Mr Simpson's performance hurdles have been achieved prior to the AGM, hence, share price on grant date of $0.195 has been determined as fair value per option.

Risk-Free rate: Observed by reference to Commonwealth Government securities for the applicable periods.

25 Reserves (continued)

Employee options

Senior management employees incentive plan
On 30 May 2025, the Board of Directors approved the issue of 44,500,786 options to senior management employees, following the recommendation from the Remuneration and Nomination Committee Meeting held on 8 May 2025 as per below:

Grant date	Number of options	Hurdle price	Exercise price	Expiry date	Fair value ($)
1-Jan-25	4,642,858	$0.330	$0.220	31-Dec-32	371,429
1-Jan-25	9,285,714	$0.440	$0.220	31-Dec-33	1,021,429
1-Jan-25	9,285,714	$0.770	$0.220	31-Dec-34	1,207,143
21-Apr-25	1,250,000	$0.330	$0.220	21-Apr-33	133,750
21-Apr-25	2,500,000	$0.440	$0.220	21-Apr-34	352,500
21-Apr-25	2,500,000	$0.770	$0.220	21-Apr-35	365,000
20-Jun-25	250,000	$0.330	$0.220	20-Jun-33	43,750
20-Jun-25	500,000	$0.440	$0.220	20-Jun-34	103,500
20-Jun-25	500,000	$0.770	$0.220	20-Jun-35	103,500
18-Jun-25	4,595,500	$0.330	$0.000	18-Jun-32	1,020,201
18-Jun-25	4,595,500	$0.440	$0.000	18-Jun-32	1,093,729
18-Jun-25	4,595,500	$0.770	$0.000	18-Jun-32	1,079,943
	44,500,786				6,895,874

The hurdle price for the options issued are based on the company's 15-day VWAP share price.

The fair value of the options has been calculated on the basis of the Monte Carlo model using the following key assumptions:

Grant date	Number of options	Spot price	Risk-free rate (%)	Expiry date	Volatility rate (%)	Fair value ($)
1-Jan-25	4,642,858	$0.190	3.83%	31-Dec-32	110.00%	371,429
1-Jan-25	9,285,714	$0.190	3.83%	31-Dec-33	110.00%	1,021,429
1-Jan-25	9,285,714	$0.190	3.82%	31-Dec-34	110.00%	1,207,143
21-Apr-25	1,250,000	$0.225	3.29%	21-Apr-33	110.00%	133,750
21-Apr-25	2,500,000	$0.225	3.29%	21-Apr-34	110.00%	352,500
21-Apr-25	2,500,000	$0.225	3.34%	21-Apr-35	110.00%	365,000
20-Jun-25	250,000	$0.300	3.27%	20-Jun-33	110.00%	43,750
20-Jun-25	500,000	$0.300	3.27%	20-Jun-34	110.00%	103,500
20-Jun-25	500,000	$0.300	3.32%	20-Jun-35	110.00%	103,500
18-Jun-25	4,595,500	$0.300	3.27%	18-Jun-32	110.00%	1,020,201
18-Jun-25	4,595,500	$0.300	3.27%	18-Jun-32	110.00%	1,093,729
18-Jun-25	4,595,500	$0.300	3.32%	18-Jun-32	110.00%	1,079,943
	44,500,786					6,895,874

Risk-Free rate: Observed by reference to Commonwealth Government securities for the applicable periods.

For the options granted on 18 June 2025 with hurdle prices of $0.330, $0.440 and $0.770, a total of 571,500 options have been forfeited following a departure of a senior management employee as at 31 December 2025.

Shares reserve
Senior management employees short-term incentive
In January 2026, in recognition of achieving commercial targets for the six months ended 31 December 2025 and in-line with their short-term incentive targets, the Board approved the issue of 353,279 shares to two senior management employees.

25 Reserves (continued)

The shares were issued in January 2026 with the expense accrued within the six months to 31 December 2025.

The fair value of the shares has been determined using share price on the board approval date at $0.240 per share.

Forfeited shares, rights and options reserve
The forfeited share rights and options reserve is the prior reporting periods' share-based payment expense attributable to performance rights and options expired or cancelled during the current reporting period.

Movements in reserves
Movements in each class of reserve during the current and previous financial year are set out below:

	Foreign currency reserve
	$
Balance as at 1-Jul-24	(100,756)
Movements in revaluation of foreign currency	(554,215)
Balance at 30-Jun-25	(654,971)
Movements in revaluation of foreign currency	(200,199)
Balance at 31-Dec-25	(855,170)

	Shares reserve as a result of acquisitions	**Shares reserve**	**Rights reserve**	**Options reserve**	**Forfeited shares, rights and options reserve**	**Total share based payments reserves**
	$	**$**	**$**	**$**	**$**	**$**
Balance as at 1-Jul-24	83,862	-	1,297,156	911,701	8,225,691	10,518,410
Share based payments expense	18,181	-	2,094,547	3,976,325	(29,206)	6,059,847
Transfer to share capital	(101,889)	-	(1,154,575)	-	-	(1,256,464)
Transfer between reserves	(154)	-	154	-	-	-
Transfer upon forfeiture	-	-	20,722	(43,400)	22,678	-
Effect of foreign exchange	-	-	-	-	-	-
Balance at 30-Jun-25	-	-	2,258,004	4,844,626	8,219,163	15,321,793
Share based payments expense	-	297,984	785,904	2,583,257	-	3,667,145
Transfer to share capital	-	(213,197)	(1,936,378)	-	-	(2,149,575)
Transfer between reserves	-	-	-	(39,200)	39,200	-
Balance at 31-Dec-25	-	84,787	1,107,530	7,388,683	8,258,363	16,839,363

26 Accumulated losses

	31-Dec-25	**30-Jun-25**
	$	**$**
Accumulated losses at the beginning of the financial year	(22,982,485)	(84,598,795)
Technical adjustment to share capital	-	81,503,186
Losses after income tax expense for the year	(17,851,299)	(19,886,876)
Accumulated losses at the end of the financial year	**(40,833,784)**	**(22,982,485)**

The details in relation to the technical adjustment to share capital is explained in note 24.

27 Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

28 Remuneration of auditors

The consolidated entity's auditors, RSM Australia Pty Ltd (RSM) supplied the below audit and non-audit services during the reporting period. BDO Audit Pty Ltd (BDO) were resigned as auditors effective 20 December 2024.

	31-Dec-25	30-Jun-25
	$	$
Audit services		
Audit or review of the financial statements - BDO	-	30,658
Audit of the space grant acquittal - BDO	-	-
Audit or review of the financial statements - RSM	115,000	150,000
Non-audit services		
Tax advice on international payroll for employees - BDO	-	-
Corporate finance matters - RSM	-	4,000
	115,000	**184,658**

29 Cash flow information

Reconciliation of loss after income tax to net cash flows from operating activities

	6 months ended 31-Dec-25	12 months ended 30-Jun-25
	$	$
Loss after income tax expense for the year	(17,851,299)	(19,886,876)
Adjustments for:		
Depreciation and amortisation	555,224	342,415
Notional interest on other liabilities	80,604	127,473
Share based payments expense	3,667,145	6,026,275
	(13,548,326)	(13,390,713)
Changes in operating assets and liabilities:		
(Increase) / decrease in trade and other receivables	(614,201)	292,804
(Increase) / decrease in inventories	789,299	(1,488,967)
(Increase) / decrease in other current assets	479,344	(591,126)
Increase / (decrease) in trade payables	(745,628)	(231,573)
Increase / (decrease) in provisions	260,921	104,251
Increase / (decrease) in other liabilities	(1,481,261)	741,593
Increase / (decrease) in provision for tax	-	(158,483)
Net cash used in operating activities	(14,859,851)	(14,722,215)
Non-cash investing activities		
Additions to the right of use assets	-	2,724,670
Additions to property, plant and equipment	152,434	11,220,565
Non-cash operating and financing activities		
Insurance prepayments funded through a premium funding arrangement	-	403,919

30 Key management personnel

Compensation

The aggregate compensation made to directors and other members of key management personnel of the consolidated entity is set out below:

	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Short-term employee benefits	1,711,506	2,779,169
Post-employment benefits	80,510	152,064
Long-term benefits	470	(5,753)
Share-based payments	2,654,982	5,266,944
	4,447,468	8,192,424

The above Key Management Personnel disclosures represent the remuneration of Key Management Personnel defined in the Remuneration Report and paid or payable for the 6 months ended 31 December 2025 and 12 months ended 30 June 2025.

For more information on Key Management Personnel Compensation disclosed under the Corporations Act 2001, please refer to Remuneration Report contained within the Directors' Report.

31 Interests in subsidiaries and joint ventures

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly owned subsidiaries in accordance with the accounting policy described in note 1:

Name	Principal place of business / Country of incorporation	Ownership interest 31-Dec-25 %	Ownership interest 30-Jun-25 %
Titomic USA Inc. (previously Tri-D Dynamics Inc.)	United States of America	100.00	100.00
Titomic Europe B.V. (previously Dycomet Europe B.V.)	Netherlands	100.00	100.00
Repkon Titomic Üretim Teknolojileri Sanayi Ve Ticaret Anonim Şirketi (Repkon Joint Venture)	Turkey	49.00	49.00

32 Commitments

	31-Dec-25 $	30-Jun-25 $
Capital commitments		
Committed at the reporting date but not recognised as liabilities, payable:		
Inventories & equipment	6,136,388	1,720,784

As at 31 December 2025 the consolidated entity had commitments of $3,725,472 in relation to expansion of Huntsville facility in the U.S. including components related to high pressure spray cold spray systems, $2,267,398 in relation to procuring material which will be partially utilised to fulfil a development contract with a U.S. defense prime, $95,644 in relation to the Netherlands facility and $47,874 in relation to the Australian facility.

33 Parent entity information

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income	**31-Dec-25**	**30-Jun-25**
	$	**$**
(Loss) after income tax	(31,367,498)	(29,182,440)
Total comprehensive income / (loss)	(31,367,498)	(29,182,440)
Statement of financial position		
Total current assets	30,289,599	11,257,796
Total assets	31,935,117	12,330,781
Total current liabilities	5,456,530	5,635,750
Total liabilities	7,242,863	7,313,348
Equity		
Issued capital	72,655,460	23,130,711
Reserves	16,839,363	15,321,793
Retained earnings	(64,802,569)	(33,435,071)
Total equity / (deficiency)	24,692,254	5,017,433

Contingent liabilities
The parent entity has no contingent liabilities towards the acquisition cost of its subsidiaries as disclosed in note 8.

Capital commitments
As at 31 December 2025, the parent entity had a commitment of $47,874 in relation to the Australian facility (30 June 2025: $1,222,627).

Significant accounting policies
The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 1, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries
As at 31 December 2025, the parent entity has provided a guarantee of $1,402,525 (30 June 2025: $Nil) in relation to the performance obligations of one of its subsidiaries.

On 4 December 2025, the parent entity entered a guarantee agreement with Samenwerkingsverband Noord-Nederland, in support of Titomic Europe B.V. performance obligations toward 3D Print Kompass Project, with an amount capped at $1,402,525 (EUR €800,000) being the total value of the grant funds to be received.

34 Related party transactions

Parent entity
Titomic Limited is the parent entity.

Subsidiaries
Interest in subsidiaries are set out in note 31.

Key management personnel
Disclosures relating to key management personnel are set out in note 30 and the remuneration report included in the directors' report.

Transactions with related parties
The following transactions occurred with related parties:

	6 months ended 31-Dec-25 $	12 months ended 30-Jun-25 $
Payment for considerations related to Dycomet B.V. acquisition (purchased from an entity controlled by Klaas Rozema)	-	263,935
Payment for lease and ongoing rental of old Netherlands manufacturing facility to De Seisde Verhuur (related entity of Klaas Rozema)	39,779	58,764
Payment for corporate and administrative costs to Obsidian, LLC. (related entity of Patricia Dare)	705,679	1,059,955
Payment for services to Vincent Ricardel (related entity of Mira Ricardel)	9,313	-
	754,771	1,382,654

In November 2021, Titomic acquired 100% of the ordinary shares of Dycomet B.V. (now Titomic Europe B.V.) controlled by Mr Rozema, details of which are explained in note 23.

After the acquisition of Dycomet B.V. in November 2021, the consolidated entity continues to pay De Seide Verhuur, a related entity of Mr Rozema, for lease of existing manufacturing site in Akkrum, Netherlands.

Titomic USA, Inc. entered into a consulting service agreement with Obsidian, LLC., a company in which Ms Dare is a director. Obsidian have provided back office support, office space, and other sales, general and administrative services to Titomic USA, Inc. prior to the new premises being available. Obsidian also has employed several employees prior to them commencing with Titomic USA, Inc and still does so as at year end in relation to some services.

Titomic USA, Inc. has employed Vincent Ricardel, a related party of Ms Ricardel, for photography and media services related to Heerenveen opening.

Loans to/from related parties
There were no loans to or from related parties at the current and previous reporting date.

Terms and conditions
All transactions were made on normal commercial terms and conditions and at market rates.

35 Contingent liabilities and contingent assets

As announced on December 6, 2022, Titomic Limited was served with a Summons filed with the Supreme Court of NSW which names the Plaintiff as Composite Technology R&D Pty Ltd ABN 52 094 571 187 and the Defendant as Titomic Limited. The claim set out in the Summons is an allegation of commercially misleading conduct which the Company denies and continues to vigorously defend. Titomic Limited has filed its defence to the Summons and has now issued a Cross Claim Summons (this was updated on 5 February 2026). Both Titomic Limited's and Composite Technology R&D Pty Ltd's lay evidence has been served. Composite Technology has been ordered to provide security for Titomic Limited’s costs of the proceedings in the amount of $1,106,600 ($1,006,000 ordered on May 23, 2025 and a further $100,000 ordered on November 27, 2025), by payment into court. The amount of $1,006,600 was paid by Composite Technology in August 2025 and an additional $100,000 is due on February 26, 2026. The directors are of the opinion that Titomic Limited will successfully defend the allegations set out in Composite Technology R&D Pty Ltd's claim, but have accounted for a provision of legal fees at 31 December 2025.

The Directors of the consolidated entity are not aware of any other significant contingencies at the balance sheet date other than a requirement for the payment of royalties pursuant to a certain license agreement, disclosed in note 23, should future revenues exceed predetermined thresholds.

The consolidated entity has no contingent assets as at 31 December 2025 (30 June 2025: $Nil).

36 Events after the reporting period

There is no matter or circumstance that has arisen since 31 December 2025 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Titomic Limited
Consolidated Entity Disclosure Statement
As at 31 December 2025

The consolidated entity provides the following information in accordance with *Corporations Act 2001* s295(3A(a)):

Name	Relationship	% Ownership	Entity type	Country of Incorporation	Tax Jurisdiction
Titomic Limited	Parent	N/A	Body corporate	Australia	Australia
Titomic USA Inc.	Subsidiary	100%	Body corporate	United States of America	United States of America
Titomic Europe B.V.	Subsidiary	100%	Body corporate	Netherlands	Netherlands

Basis of Preparation

This Consolidated Entity Disclosure Statement (CEDS) has been prepared in accordance with the Corporations Act 2001. It includes certain information for each entity that was part of the consolidated entity at the end of the financial year.

Determination of Tax Residency

Section 295 (3A) of the Corporations Acts 2001 defines tax residency as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgement as there are currently several different interpretations that could be adopted, and which could give rise to a different conclusion on residency. It should be noted that the definitions of 'Australian resident' and 'foreign resident' in the Income Tax Assessment Act 1997 are mutually exclusive. This means that if an entity is an 'Australian resident' it cannot be a 'foreign resident' for the purposes of disclosure in the CEDS.

In determining tax residency, the consolidated entity has applied the following interpretations:

Australian tax residency

The consolidated entity has applied current legislation and judicial precedent, including having regard to the Tax Commissioner's public guidance in Tax Ruling TR 2018/5.

Foreign tax residency

Where necessary, the consolidated entity has used independent tax advisers in foreign jurisdictions to assist in determining tax residency and ensure compliance with applicable foreign tax legislation.

Titomic Limited
Directors' Declaration
For the six months ended 31 December 2025

In the directors' opinion:

- the attached financial statements and notes and the remuneration disclosures that are contained within the Remuneration report within the Directors' report comply with the *Corporations Act 2001* , the Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements;

- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;

- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2025 and of its performance for the financial year ended on that date;

- there are reasonable grounds to believe that the consolidated entity will be able to pay its debts as and when they become due and payable, subject to the matters disclosed under going concern in note 1 to the financial statements; and

- the attached consolidated entity disclosure statement is true and correct.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors

Dag W.R. Stromme
Chair
Titomic Limited

27 February 2026

RSM Australia Partners

Level 27, 120 Collins Street Melbourne VIC 3000
PO Box 248 Collins Street West VIC 8007

T +61 (0) 3 9286 8000
F +61 (0) 3 9286 8199

www.rsm.com.au

INDEPENDENT AUDITOR'S REPORT
To the Members of Titomic Limited

REPORT ON THE AUDIT OF THE FINANCIAL REPORT

Opinion

We have audited the financial report of Titomic Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2025, the consolidated statement of profit and loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the six-month period then ended, and notes to the financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion the accompanying financial report of the Group is in accordance with the Corporations Act 2001, including:

i. giving a true and fair view of the Group's financial position as at 31 December 2025 and of its financial performance for the six-month period then ended; and

ii. complying with Australian Accounting Standards and the Corporations Regulations 2001.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (*including independence standards*) (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matter	How our audit addressed this matter
Recognition of Revenue Refer to Note 6 in the financial statements	
Revenue for the six months period ended 31 December 2025 was $5,270,650. Revenue is considered to be a Key Audit Matter because of: • the identification of performance obligations, • the method of recognition of revenue (over time or at a point in time); and • revenue is generated from varying income sources, with different recognition patterns requiring management estimates.	Our audit procedures in relation to the recognition of revenue included: • assessing whether the Group's revenue recognition policies are in compliance with AASB 15 *Revenue from Contracts with Customers*; • evaluating the operating effectiveness of management's controls related to revenue recognition; • for a sample of revenue transactions, substantiating transactions by agreeing to supporting documentation, including customer contracts and ensuring they are accounted for in line with the revenue recognition policy; • assessing revenue transactions before and after year-end to ensure that revenue is recognised in the correct period; and • assessing the appropriateness of the disclosures in the financial report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the six-month period ended 31 December 2025, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of:

a. the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001; and

b. the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and

for such internal control as the directors determine is necessary to enable the preparation of:

i. the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and

ii. the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf This description forms part of our auditor's report.

REPORT ON THE REMUNERATION REPORT

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 27 to 36 of the directors' report for the six-month period ended 31 December 2025.

In our opinion, the Remuneration Report of Titomic Limited., for the six-month period ended 31 December 2025, complies with section 300A of the Corporations Act 2001.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

RSM AUSTRALIA PARTNERS

B Y CHAN
Partner

Date: 27 February 2026
Melbourne, Victoria

Titomic Limited
Shareholder Information
For the six months ended 31 December 2025

Corporate Governance Statement

The Company's Directors and management are committed to conducting the business of the consolidate entity in an ethical manner and in accordance with the highest standards of corporate governance. The Company has adopted and substantially complies with the *ASX Corporate Governance Principles and Recommendations* (Fourth Edition) (**Recommendations**) to the extent appropriate to the size and nature of the Group's operations.

The Company has prepared a statement which sets out the corporate governance practices that were in operation throughout the financial year for the Company, identifies any Recommendations that have not been followed, and provides reasons for not following such Recommendations (**Corporate Governance Statement**).

In accordance with ASX Listing Rules 4.10.3 and 4.7.4, the Corporate Governance Statement will be available for review on the Company's website (www.titomic.com), and will be lodged together with an Appendix 4G with the ASX at the same time that this Annual Report is lodged with the ASX.

The Appendix 4G will particularise each Recommendation that needs to be reported against by the Company and will provide shareholders with information as to where relevant governance disclosures can be found.

The Company's corporate governance policies and charters are all available on the Company's website (www.titomic.com).

Additional Securities Information

In accordance with ASX Listing Rule 4.10, the Company provides the following information to shareholders not elsewhere disclosed in this Annual Report. The information provided is current as at 23 February 2026 (**Reporting**

Quoted equity securities - ordinary shares

As at the Reporting Date, the Company had a total of 1,606,096,794 fully paid ordinary shares on issue. The Company's shares are quoted on the ASX, and form the only class of securities on issue in the Company that is quoted on the ASX, and that carries voting rights.

At a general meeting of the Company, every holder of ordinary shares is entitled to vote in person or by proxy or attorney; and on a show of hands (every person present who is a member has one vote); and on a poll (every person present in person or by proxy or attorney has one vote for each ordinary share they hold).

Range of holdings

An analysis of the number of shareholders in the Company by size of holding is as follows:

Share Range	**Number of Holders**	**Units**	**%**
1-1,000	753	369,837	0.023%
1,001-5,000	1,663	4,812,650	0.300%
5,001-10,000	817	6,557,764	0.408%
10,001-100,000	1,749	66,179,967	4.121%
100,001 and over	727	1,528,176,576	95.148%
Total	5,709	1,606,096,794	100.000%

Unmarketable Parcels

The number of shareholders holding less than a marketable parcel of shares as at the Reporting Date (based on a closing price of $0.200 per share) was 1,500 shareholders (holding 1,723,150 ordinary shares).

Titomic Limited
Shareholder Information
For the six months ended 31 December 2025

Top 20 Shareholders

The names of the 20 largest holders of ordinary shares as at the Reporting Date are listed below:

Rank	Name	No. of shares	%
1	CITICORP NOMINEES PTY LIMITED	341,984,309	21.293%
2	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED - A/C 2	165,740,147	10.319%
3	QUALITY LIFE PTY LTD <THE NEILL FAMILY A/C>	60,000,010	3.736%
4	UBS NOMINEES PTY LTD	58,299,933	3.630%
5	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	55,515,107	3.457%
6	PATRICK BERGIN SMSF PTY LTD <PATRICK BERGIN SMSF A/C>	43,087,757	2.683%
7	MR PATRICK THOMAS BERGIN	39,856,959	2.482%
8	MR HUMPHREY WILLIAM MARDEN NOLAN	35,000,000	2.179%
9	GLENEAGLE SECURITIES NOMINEES PTY LIMITED	33,656,087	2.096%
10	DR ANDREAS GEORG SCHWER	30,115,384	1.875%
11	VELROSSO PTY LTD <HARVEY 1995 A/C>	23,956,184	1.492%
12	HERBERT KOECK	23,736,506	1.478%
13	REPKON MAKINA VE KALIP SANAYI VE TICARET ANONIM SIRKETI	23,661,078	1.473%
14	J P MORGAN NOMINEES AUSTRALIA PTY LIMITED	21,384,949	1.331%
15	BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT>	18,366,716	1.144%
16	MR HUMPHREY WILLIAM MARDEN NOLAN	17,500,000	1.090%
17	WARBONT NOMINEES PTY LTD <UNPAID ENTREPOT A/C>	14,692,835	0.915%
18	QUALITY LIFE PTY LTD <THE NEILL FAMILY A/C>	14,328,333	0.892%
19	RED DOG #1 PTY LTD <RED DOG A/C>	12,570,000	0.783%
20	MR MARK PHILIP ARNOLD	12,000,000	0.747%
	Total	**1,045,452,294**	**65.093%**
	Balance of register	**560,644,500**	**34.907%**
	Grand total	**1,606,096,794**	**100.000%**

Substantial Shareholders

Substantial shareholders as advised to the Company are set out below:

Name	No. of shares	%	Current at (last notification date)
Maybank Securities	154,500,027	9.62%	28-Nov-25
Regal Funds Management Pty Ltd	117,089,438	7.29%	31-Jul-25
Quality Life Pty Ltd	69,242,275	4.31%	9-Dec-24

Escrowed securities

There are no escrowed securities in the Company as at the Reporting Date.

Unquoted equity securities

The Company has two classes of unquoted equity securities on issue, being Performance Rights and Options.

Performance Rights

The Performance Rights will vest into ordinary shares (on a 1-for-1 basis), subject to satisfaction of prescribed vesting conditions.

None of the Performance Rights carry any voting rights. However, any underlying shares issued upon the vesting or conversion of the Performance Rights will carry equal voting rights with the other share on issue in the Company.

Titomic Limited
Shareholder Information
For the six months ended 31 December 2025

As at the Reporting Date, there were a total of 1,250,000 Performance Rights on issue, held by one holder.

An analysis of the number of Performance Rights holders by size of holding is as follows:

Range	Number of Holders	Units	%
1-1,000	-	-	-
1,001-5,000	-	-	-
5,001-10,000	-	-	-
10,001-100,000	-	-	-
100,001 and over	1	1,250,000	100.000%
Total	1	1,250,000	100.000%

Options

The Options upon exercise will convert into ordinary shares (on a 1-for-1 basis), subject to various exercise prices and expiry dates.

None of the Options carry any voting rights. However, any underlying shares issued upon the vesting or conversion of the Options will carry equal voting rights with the other share on issue in the Company.

As at the Reporting Date, there were a total of 202,041,786 Options on issue, held by 67 holders.

An analysis of the number of Option holders by size of holding is as follows:

Range	Number of Holders	Units	%
1-1,000	-	-	-
1,001-5,000	1	3,562	0.002%
5,001-10,000	1	10,000	0.005%
10,001-100,000	30	1,580,753	0.782%
100,001 and over	35	200,447,471	99.211%
Total	67	202,041,786	100.000%

Shareholder enquiries

Shareholders with enquiries about their shareholdings should contact the share registry:
Computershare
GPO Box 3224
Melbourne VIC
Phone 1300 850 505

Shareholder enquiries

Shareholders should contact the share registry to obtain details of the procedure required for these changes.

Annual Report mailing list

We encourage shareholders to update their preferences to opt-out of receiving a hard copy of the Annual Report by contacting the share registry.

Titomic Limited
Corporate directory
For the six months ended 31 December 2025

Directors	Mr Dag W.R. Stromme *(Executive Chair)* Mr Humphrey Nolan *(Independent Non-Executive Director)* Mr Andreas Schwer *(Independent Non-Executive Director)* Ms Mira Ricardel *(Independent Non-Executive Director)* Mr John Frewen, AO, DSC *(Independent Non-Executive Director) (appointed 1 July 2025)* Mr Jim Simpson (*Managing Director)*
Company Secretary	Mr Geoff Hollis
Principal Place of Business and Global Headquarters (United States of America)	15091 Al Hwy 20 Madison, Huntsville, AL 35756
Registered Office and principal place of business (Australia)	Unit 1, 371 Ferntree Gully Road Mount Waverley, Victoria, 3149, Australia
Principal Place of Business (The Netherlands)	Mars 14 8448 CP, Heerenveen The Netherlands
Share Registry	Computershare GPO Box 3224 Melbourne, Victoria, 3001, Australia
Auditors	RSM Australia Partners Level 27, 120 Collins Street Melbourne, Victoria, 3000, Australia
ASX ticker	ASX: TTT
Website	http:/titomic.com/